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Molecular design of novel pharmaceutical agents depends on a mechanistic
paradigm. A library of compounds was designed to mimic some features of cisplatin that
are believed to be in part responsible for its success as a chemotherapeutic agent against
testicular cancer. The new compounds are designed to utilize proteins such as steroid
receptors that are abnormally expressed in cancers to enhance toxicity and specificity.
The synthetic phase of this project successfully produced a compound, 11P, that when
tested against cancer cell lines demonstrated remarkable potency, including the induction
of apoptosis in normally apoptosis-resistant prostate cancer lines. This drug candidate,
comprising an aniline mustard tethered to a steroid moiety, is intended to form covalent
adducts with DNA that, through association with the androgen receptor over-expressed in
some prostate cancers, are likely to be shielded from repair, generating lethal crosslinks.
Moreover, the titration of androgen receptor away from its normal function as a
transcription factor may further inhibit tumor growth.
While the mechanistic features of I1P are still under investigation, the potent anti-
cancer activity warrants consideration of its possible clinical use, specifically against
hormone-refractory, metastatic prostate cancer, for which current therapeutic options are
extremely limited. One important step toward that goal involves characterizing the
pharmacokinetics of the compound, including: a) understanding the rate of hydrolytic
decomposition, b) evaluating the metabolic conversion by intracellular enzymes to active
or inactive derivatives, and c) exploring the potential for contraindications between this
drug candidate and other medications a prostate cancer patient may be taking
concurrently.
Herein are described the experiments that elucidate the pharmacokinetics of 1I1,
showing that the drug candidate is a) subject to hydrolysis at rates that depend on the
presence of plasma protein; b) extensively metabolized by the cytochromes P450 to
products demonstrating reduced capacity for forming covalent adducts with DNA; and c)
a potent inhibitor of the metabolism of known substrates of the 2D6 and 3A isoforms of
cytochrome P450.
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C hapter 1: Introduction to the Design, Efficacy, and
Pharmacology of 11p-dichloro, a Programmable
Genotoxicant against Human Prostate Cancer
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Prostate Cancer
Among the leading killers of men in the United States, adenocarcinoma of the
prostate is a peculiar disease, originating in a non-essential gland whose function is only
partially understood, and frequently progressing so slowly as to make "watchful waiting"
a primary strategy upon diagnosis'. In 2008, over 185,000 new cases were diagnosed,
2making prostate cancer the most common cancer in men2. Prostate cancer is second only
2to lung cancer in mortality, causing 10% (>28,000) of all cancer deaths in men.
The prostate gland, normally about the size of a golf ball, surrounds the urethra at
the base of the bladder, and serves to nourish sperm with a variety of micronutrients and
proteins3 . The transient gelatinous consistency of human semen is created by
semenogelin I4 and degraded by human seminal proteinase5 , also known as prostate-
specific antigen (PSA)6 . Over the last two decades, screening for PSA levels in the blood
of men over the age of fifty has become standard practice in diagnostic oncology since
the initial discovery 7 of a strong correlation between prostate tumor volume and
circulating PSA levels. The increased frequency and reliability of this test has improved
the rate of detection of neoplasia, made more precise the distinction between neoplasia
and benign prostate hyperplasia (BPE), and lowered the average stage at which cancer is
diagnosed, as evidenced by the downturn from peak incidence (>300,000) and death
(40,000) rates attributed to prostate cancer in 19968. Before PSA screening, patients
would not likely be diagnosed with prostate cancer until the presentation of clinical
symptoms or detection of nodules by digital rectal examination (DRE).
A positive (>4 ng/mL) PSA screen will provoke a DRE to explore the peripheral
zone of the gland where tumors are more likely to occur followed by a multifocal biopsy
to assess the degree of uniformity and differentiation of the prostatic epithelia. Based on
the histology, the patient will be given a Gleason score between two and ten, calculated
by summing the Gleason grades describing the levels of differentiation observed in the
two largest areas of the tissue sample. A Gleason grade of 1 represents uniform, closely-
packed, well-differentiated glands, while a Gleason grade of 5 indicates a complete loss
of organ morphology9 . A combined Gleason score of 9 or 10 or a single Gleason grade
of 5 indicate the poorest prognosis for patient survival0 , likely describing tumors that
have already metastasized or will soon metastasize to distant foci, most commonly bone
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and lymph nodes. While elevated PSA levels are correlated with an increase in prostate
size, the distinction between BPE and prostate cancer, as well as the assessment of the
aggressiveness of a tumor, may be more accurately characterized by the rate of increase
rather than the absolute levels of PSA in plasma". The trio of Gleason score, kinetics of
PSA expression, and tumor stage combine to characterize the risk stratification of the
disease and guide the selection of a therapeutic course".
Detection preceding metastasis allows a full slate of targeted treatment options,
including androgen ablation achieved chemically or through bilateral orchiectomy,
radical prostatectomy, or radiation therapy. Typically, if the tumor has not penetrated the
prostatic capsule, surgical resection of the gland is preferred 3 . If instead tumor cells
have progressed to the point of being able to infiltrate neighboring tissues, external beam
radiation' 4 , brachytherapy , and/or intensity-modulated radiation 1',1 may target the
diseased prostate and surrounding invasions'8 . Once a prostate tumor has metastasized,
however, systemically-delivered drugs are the only remaining treatment strategy.
Prostate cancer is one of several human cancers arising in tissues dependent on
steroid hormones for cell cycle regulation. The regulation of the distribution and function
of steroids is holistic and inherently tissue-specific. While all of these hormones are
derived from cholesterol' 9, sharing common synthetic machinery across diverse tissue
types, the signal transduction pathways actuated by each individual steroid are tightly
controlled by glandular feedback mechanisms to maintain healthy adult homeostasis.
Gonadotropin-releasing hormone (GnRH) secreted by the hypothalamus promotes the
release of follicle-stimulating hormone (FSH) and luteinizing hormone ~(LH) from the
anterior pituitary. FSH and LH in turn incite the testicles to produce testosterone, which,
once released into the blood stream, is sufficiently hydrophobic to cross the blood-brain
barrier and repress the further production and release of GnRH, FSH, and LH'n
Circulating testosterone diffuses into prostate epithelia and is converted by 5a-reductase
type 1I in the smooth endoplasmic reticulum to dihydrotestosterone (DHT)22,23, which,
with seven-fold higher affinity for the androgen receptor (AR)24, is the primary ligand
associated with signal transduction. Once bound to ligand, androgen receptor
dissociates from chaperone heat shock proteins Hsp90 and Hsp70 26 and forms a
homodimer27,28 phosphorylated by various kinases. Phosphorylated homodimer
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translocates to the nucleus to promote gene transcription through binding to cognate
sequences in the genomic DNA known as androgen-response elements (AREs) 29. This
AR-mediated gene transcription is the primary growth-promoting impetus in prostate
tissue; the goal of anti-androgen therapy is either to remove steroids completely through
physical or chemical castration, or to compete directly with AR binding sites to squelch
the signal and disrupt cell cycling (Figure 1-1).
Since the majority of prostate tumors demonstrate a high level of AR expression,
and the signaling effects of the androgen receptor bound to its ligand can promote the
further growth of the cancerous cells, androgen ablation will always be preferred to
comparatively invasive or toxic therapy options. Extended treatment with anti-
androgens, however, eventually provokes progression to androgen-independent tumors
that can be effectively attacked only by administration of cytotoxicants. To confound
matters, a negative PSA screen may miss the presence of an already-androgen-insensitive
tumor, as PSA expression depends on AR-promoted transcription. A combination of
30PSA screening and DRE is now believed to most reliably detect prostate cancer
Acquisition of androgen-insensitivity may occur through one or more of several
mechanisms: mutation, leading to dysregulation of the ligand-receptor binding
specificity3 1 ; adaptation, caused by up-regulation of the growth-promoting signaling
cascade through changes in gene expression ; or selection, in which pre-existing
androgen-independent cancer stem cells undergo clonal expansion even in the absence of
hormone signal, replacing their dying androgen-dependent counterparts during a period
of tumor macrostasis (or regression) 33. No matter which mechanism is responsible for
the progression, once it occurs, prognosis is at its nadir, with the only remaining
therapeutic window being the differential between the division rates of cancerous and
healthy tissue. Rapidly-dividing tumor cells cannot withstand the antineoplastic agents
that block DNA replication, while most healthy adult tissue is not actively dividing and
can therefore sustain and repair DNA damage. The adult tissue that is not static is
susceptible to the slate of side effects that limit therapy.
The most common chemical agents used to treat PC include the anti-androgens,
comprising steroidal (cyproterone acetate) and non-steroidal (bicalutamide, flutamide)
direct AR competitors (Figure 1-2a) as well as the hormone regulation disruptors
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leuprolide and ketoconazole (Figure 1-2b); the anti-mitotic microtubule inhibitors
estramustine phosphate and docetaxel (Figure 1-2c); and the DNA replication inhibitors,
including the topoisomerase inhibitor mitoxantrone (Figure 1-2d). The progression of
prostate disease from early-stage, androgen-dependent neoplasia to invasive, androgen-
independent metastatic cancer necessitates a commensurate evolution of treatment
strategies (Figure 1-3).
There exists an opportunity to widen the therapeutic window through the clever
design of toxicants that exploit the phenotypic aspects of prostate cancer. The growth
signaling associated with the normal function and trafficking of the androgen receptor is
mediated by its promotion of the transcription of genes that lead to progression through
the cell cycle. Diversion of the receptor from its function as a transcription factor should
slow the rate of division, but in cancers that have achieved androgen-independence, this
functionality is lost. However, the continued presence of a high level of androgen
receptor, even in distant metastatic foci 34, suggests that a drug candidate whose toxicity is
facilitated or enhanced by interaction with the receptor should kill selectively those tumor
cells-regardless of metastatic milieu-that arose from prostate tissue.
Cisplatin and Testicular Cancer
One of the brightest success stories in the centuries-old fight against human
cancers comes from the mechanism of toxicity of cis-diamminedichloroplatinum(II)
(cisplatin), a bifunctional, platinum-containing DNA-damaging agent central to the 93%
cure rate for testicular cancer 35 . Unlike its non-cytotoxic and therapeutically ineffective
trans isomer, cisplatin is capable of coordinating adjacent purines at the N7 position of
each base. The resulting kink in the DNA backbone is bound with strong affinity
(KD 60 pM) 36 by the human upstream binding factor (hUBF), a high mobility group
(HMG) domain-containing protein associated with the promotion of transcription of
ribosomal RNA through recognition of RNA polymerase I. This affinity is comparable
(KD ~ 18 pM) 36 to the association between hUBF and the cognate response element
upstream of the gene encoding ribosomal DNA. While there are many mechanisms that
have been proposed for cisplatin, the data on protein binding37 suggested two novel ones
(Figure 1-4). First, hUBF or another adduct-binding protein shields the adduct from
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nucleotide excision repair38. Second, the simple titration of hUBF or other transcription
factors away from their normal function as regulators of tumor gene expression
contributes to dysregulation of the cell cycle39
One branch of the development of next generation anti-cancer drugs seeks to
mimic the mechanistic success of cisplatin against testicular cancer in other tissue
backgrounds, creating a way either to deliver far less drug while achieving the same
toxicity to tumor cells, or to increase the dosage level to kill tumors more effectively
while maintaining the same level of side effects as traditional chemotherapy.
Conventional alkylating agents, developed from mustard gas, are spectacularly toxic to
all dividing tissues, cancerous or healthy. Patients receiving nitrogen mustards hope that
the drugs kill their tumors before killing them-the collateral toxicity to normally-
renewing tissues, especially myelosuppression 0 , is often the limiting factor in clinical
settings.
DNA Alkylating Agents
Alkylating agents are most frequently used in combination with other
chemotherapeutic agents, delivered as part of empirically-derived regimens that balance
tumor-killing efficacy against the side effects suffered by patients. Among these agents
are the aniline mustards, including melphalan, used clinically against multiple
myelomall, and chlorambucil, central to the treatment of chronic lymphocytic leukemia4 2
and non-Hodgkin's lymphoma 3 . Mechanistically, attack by the aniline nitrogen on
either terminal carbon displaces its chloride leaving group, yielding an electrophilic
aziridinium ion. This moiety is susceptible to attack by the nucleophilic sites of
biological macromolecules, including several positions on DNA, with N7 of guanine
most commonly forming the covalent bond. Held in close proximity to DNA, a second
nucleophilic attack can yield a crosslink that, if persistent, can elicit cell cycle arrest
and/or cytotoxicity by blocking DNA replication or assaulting genomic structural
integrity through creation of a double-strand break. Human cancers treated with
alkylating agents can acquire drug resistance, reducing the efficacy of these compounds
through the up-regulation of DNA repair pathways 4 or metabolic detoxification
machinery 4548 . Again, whether this proceeds through clonal selection or mutational gain-
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of-function, the timeline for a patient following growth of tumors unresponsive to these
highly toxic drugs is grim.
Design of Programmable Genotoxicants
Researchers in the drug design field strive to make cancer therapeutics that
selectively kill tumor cells while leaving healthy tissue intact. The over-expression of
specific proteins in certain cancers has provided a plan of attack: compounds toxic in the
presence of a steroid receptor more abundant in cancerous tissue than in non-diseased
cells should be more effective chemotherapeutic agents than drugs whose toxicity is
independent of receptor expression. The abundance of androgen receptor in prostate
tissue suggests that a compound whose toxicity requires-or is at least enhanced by-
interaction with the receptor would make a useful agent in achieving selectivity.
Cytotoxic agents linked to steroid moieties, such as estramustine and prednimustine4 9 ,
have been developed with the goal of achieving selective delivery, hormone antagonism,
or stability enhancement, but the deleterious interaction between a transcription factor
and a site of DNA damage in the mechanism of cisplatin represented a novel
pharmaceutical design strategy.
The Essigmann Laboratory, recognizing this opportunity for innovation in the
treatment of several kinds of cancer, has taken a combinatorial approach to the design of
these programmable genotoxicants, seeking to optimize through chemistry the potency of
the alkylating agents, stability of the linkers, and affinity to target receptors of the ligand
analogs. This library comprises aniline mustards and platinum centers50 as alkylating
"warheads," a series of solubility-enhancing linkers of various functionalities and lengths
designed to optimize the interaction between the receptor and the DNA adductl, and
ligands for the androgen 2 and estrogen3,54 receptors to combat prostate, breast, and
ovarian cancers (Figure 1-5). The efficacy of cisplatin arises from its multiple
mechanisms and their inherent cooperation: titration of growth factor away from its
signaling cascade also shields toxic DNA lesions from repair. The programmable
genotoxicants designed in the Essigmann Laboratory are designed to achieve a similar
multi-functionality55 .
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The leading candidate against prostate cancer from this library is an 11p-
substituted estra A4(5)'9(l )-3-one linked to an NN-bis-(2-chloroethyl)-aniline by a linker
containing a carbamate synthetic handle and a solubility-enhancing secondary amine,
known as 11 p-dichlorot and abbreviated in this report as 11P. Two control compounds
with derivative versions of the nitrogen mustard were synthesized as well: I11-
dimethoxy, incapable of any DNA alkylation, and 11 p-monochloro-monomethoxy
(monochloro), capable of forming a covalent adduct with DNA but lacking the second
chloroethyl arm necessary for the formation of DNA crosslinks. The relative binding
affinity (RBA) of 11p -dichloro and 11p -dimethoxy for the AR in comparison with the
standard reference synthetic androgen methyltrienolone (R1881) has been measured as
11% and 18%, respectively (Figure 1-6)52. A sixteen-base-pair DNA oligomer
containing a covalent I11 adduct was shown to have an RBA of 0.22%52, suggesting that
a sufficient adduct load may disrupt the native AR-promoted transcriptional program.
Preliminary in vitro and in vivo treatments have been performed, demonstrating
the potent toxicity of I11 against several cell lines derived from metastatic prostate
cancer, including the androgen-dependent LNCaP line56 , as well as moderate toxicity
against the AR-expressing but androgen-independent PC3 and DU-145 lines57
(Figure 1-7). Promisingly, the growth of tumors arising from LNCaP xenografts
implanted subcutaneously in a mouse model52 was strikingly inhibited by daily
administration of I1P with minimal toxicity to the host (Figure 1-8), thus provoking the
need to confirm the mechanism of toxicity and explore the pharmacokinetic behavior of
the drug candidate.
Clinical Pharmacology
The practice of drug design characterizes absorption, distribution, metabolism,
excretion, and toxicology (ADME/Tox) in order to determine the fitness of a drug
candidate for progression from bench-top screening to clinical trials. Of primary concern
is the relationship between dosage and exposure, which depends strongly on the ability of
the body to clear xenobiotic chemicals from its circulation. Clinicians monitor plasma
2-(6-((8S,11S,13S,14S,17S)-17-Hydroxy-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17 dodecahydro-iH-
cyclopenta[a]phenanthren-1 1-yl)hexylamino)ethyl 3-(4-(bis(2-chloroethyl)amino)phenyl)propylcarbamate
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concentration of a drug (or its metabolite biomarker) and derive dosage schedules that
maintain most effectively a profile within the therapeutic window of the drug-i.e.,
abundant enough to achieve a desired outcome but below the toxic threshold.
Hepatic pathways are responsible for the overwhelming majority of drug
clearance, shuttling hydrophobic molecules into bile ducts for inclusion in feces, or
converting them into more polar species for renal excretion. The biotransformation of
xenobiotics to more polar metabolites can also yield a structural chassis onto which
solubility-enhancing cofactors can be conjugated, facilitating clearance by either route.
The bulk of these reactions are catalyzed by the cytochromes, a diverse
superfamily of redox-capable hemoproteins localized to the endoplasmic reticula and
mitochondria of eukaryotes. A subset of this superfamily, the cytochromes P450,
comprises the enzymes charged with the bioactivation of drugs necessary to facilitate
clearance. These enzymes can be found in almost all epithelia, but are most abundantly
expressed in hepatocytes. The P450 family is divided into subgroups based on sequence
homology, with expression patterns varying widely at every level of examination: across
tissues58, species 9 , and ethnic groups0 '61. Members of the family are known as isoforms
and are identified with an ever-evolving system of nomenclature reflective of the levels
of sequence homology. Isoforms are abbreviated as CYP followed by a number
representing families sharing at least 40% homology, a letter representing subsets with at
least 55% homology, and a second number for an individual gene6 2,63 . For example,
CYP3A4, the most abundantly-expressed P450 isoform in humans and the enzyme
responsible for the vast majority of xenobiotic metabolic transformations, is a member of
the CYP3A 64 subset of the CYP3 family65 of genes localized to chromosome 766
The most common reaction catalyzed by the cytochromes P450 is an oxidation,
usually near a site of high electron density on the substrate. This process requires a cycle
of the oxidation states of the heme iron (Figure 1-9), with the net effect of reducing
molecular oxygen to water and inserting one oxygen atom into the substrate. While the
sequence of the conversions and roles of the cofactors are generally conserved, the
macrostructure of the enzyme governs its substrate specificity. Substrates that fit into the
active site of a given isoform are subject to a diverse array of transformations, including
hydroxylation at or near a heteroatom, oxidation of a carbon center, epoxidation of a
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carbon-carbon double bond, and even dealkylation. Each of these potential sites of
oxidation should directly enhance solubility or enable attachment of a cofactor,
effectively increasing renal or fecal clearance and lowering the area under the curve
(AUC) achieved by administration of a given dose.
In some cases, however, oxidation activates the compound, generating a reactive
intermediate that may have beneficial or deleterious biological activity. The epoxidation
of aflatoxin B1 yields an electrophile capable of forming mutagenic DNA adducts
strongly associated with the development of liver cancer (Figure 1-10a)67,68. Conversely,
the usefulness of cyclophosphamide as an anti-cancer agent depends on oxidation at the
4' position to enable the ring-opening rearrangement necessary for decomposition into the
alkylating agents phosphoramide mustard and acrolein (Figure 1-10b) 69-71. Furthermore,
oxidation by P450 expressed in prostate epithelia has been directly implicated in the
generation of DNA-damaging metabolites central to the epidemiological correlation
between diets rich in cooked meats and increased incidence of prostate cancer.
The molecular structure of a drug candidate can guide the generation of a
hypothesis toward determining the P450 isoforms for which it may be a sutistrate.
Comparison with pharmacophores-molecules containing similar structure and/or
arrangement of functional groups-yields some clues as to what the metabolic products
of a given compound may be. However, it is ultimately necessary to test metabolism
empirically by incubating a potential substrate with whole hepatocytes, liver microsomes,
or purified P450 enzymes.
Interestingly, the biosynthesis and metabolism of endogenous steroids depend on
many of the same enzymes, as the cascade from cholesterol to testosterone, estrogen, and
progesterone requires redox chemistry at several steps'9 . Because hormone therapy
against prostate cancer includes competitive inhibitors for the androgen receptor, it is
important to consider the possibility that these compounds will also be substrates 'for
steroid synthetic machinery. Furthermore, clearance of testosterone also requires
hydroxylation by P450, and subtle modifications to the steroid ring system effect
24dramatic consequences on the affinity of the molecule for the steroid receptors
Cancer therapy frequently involves combinations of drugs in tightly-controlled
patterns of administration. Hormone antagonists, cytotoxicants, and the analgesics and
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anti-emetics used to mitigate side effects are prescribed together, and it is crucial that
their co-administration does not alter the desired pharmacology of each compound. The
development of new chemotherapeutic agents must therefore consider the high
probability that, if successful, the drug candidates would eventually be administered in
combination with other agents. In addition to screening compounds through relevant
bioassays for efficacy, pharmacologists must consider drug-drug interactions (DDI) as a
potential safety hazard alongside primary toxicity caused by the compound administered
73alone
Prostate cancer patients may be suffering from a variety of conditions common in
the elderly and requiring regular administration of therapeutics. While prostatic is second
only to lung in cancer mortality rate in the developed world, cardiovascular, respiratory,
and metabolic diseases more frequently cause death and/or require chronic
pharmaceutical intervention?4. High cholesterol dramatically increases the risk of
myocardial and cerebral infarction following atherosclerotic plaque growth, making
Lipitor (atorvastatin , metabolized by CYP3A4 76), the most commonly-prescribed
medicine in the United States in 2007. Also metabolized by CYP3A4 are the anti-
inflammatory corticosteroid fluticasone 77 and the p2-adrenergic receptor agonist
salmeterol78, which are combined to treat chronic obstructive pulmonary disease as
Advair, ranked third on the most-prescribed list. Avandia (rosiglitazone, metabolized by
CYP2C879), which inhibits insulin expression by promoting the expression of peroxisome
proliferator-activated receptor gamma8 0 , is the top prescription for countering insulin
resistance in patients with type 2 diabetes mellitus.
Before even considering multiple disease states interfering with prostate cancer
treatment, it is important to note that the erectile and urinary dysfunctions81 caused by
prostate cancer surgery and radiation treatment frequently provoke the prescription of the
cGMP-phosphodiesterase inhibitor Viagra (sildenafil, metabolized8 2 by CYP3A4 and
CYP2C9), which effects localized vasodilation through the release of nitric oxide8 3, and
Flomax (tamsulosin, metabolized8 4 by CYP3A4 and CYP2D6), which lowers bladder
pressure through inhibition of the aia-adrenorecptor in prostate tissue. The non-steroidal
anti-inflammatory drug diclofenac, which reduces pain by inhibiting the arachidonic acid
cascade necessary for the synthesis of prostaglandin8 5, holds the distinction of being a
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standard anti-arthritis medication, commonly-prescribed in the maintenance of pain
associated with prostate cancer bone metastases, and widely-accepted as a standard probe
for the assessment of metabolism by CYP2C886.
The variable expression of P450 across species and individuals limits the power
of data generated from animal trials when predicting the behavior of a drug candidate in
humans. The DDI potential in a multi-drug treatment regimen may be of great concern in
one patient but inconsequential in another due to both genetically-determined expression
levels and allelic variants of the isoforms. Advances in genetic screening and
bioinformatics are personalizing the practice of medicine in all specialties, and over the
last few decades, pharmacologists have not only classified the metabolic machinery
responsible for the transformation of existing drugs, but also added the characterization
of the metabolic profile of a drug candidate to the pre-clinical checklist.
Specific Aims
The promising activity of l11 against prostate cancer cells in vitro and LNCaP
xenografts in vivo prompted systematic study of the pharmacokinetic and
pharmacodynamic properties of the drug candidate. The analysis of stability to
hydrolysis and the identification of hydrolytic decomposition products of l11 in various
aqueous systems are discussed in Chapter 2, serving as a necessary prelude to an
examination of the metabolic profile of the drug candidate as described in Chapter 3.
Metabolic exploration of 11p comprised qualitative and quantitative assessments of the
extent of conversion, spectrum of daughter compounds, and identity of P450 isoforms
catalyzing the transformations. Incubation of radio- or unlabeled compound with various
preparations of liver microsomes allowed separation and characterization of metabolites
by a combination of analytical techniques, including high-pressure liquid
chromatography, electrospray ionization-time of flight, triple quadrupole, and accelerator
mass spectrometry, and high-throughput DDI screening. Finally, preliminary
examination of the effects of formulation and delivery route on the organ-level
bioavailability of 11p as well as subcellular transport, distribution phenomena, and non-
specific binding of the drug candidate in vitro are reported in Chapter 4.
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Figure 1-1: The Hypothalamus-Pituitary-Gonadal axis regulates circulating
testosterone levels and is a target for therapeutic intervention
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Figure 1-2: Several classes of drugs are used in concert against prostate cancer
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Figure 1-2: Several classes of drugs are used in concert against prostate cancer
c) Microtubule inhibitors
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Figure 1-3: Treatment options strongly depend on the stage of progression of
prostate cancer
Stage I
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If detected at Stage It, prostate cancer is localized and may be treated through targeted
radiation or implantation of radioactive material (brachytherapy) to kill the tumor, with
radical prostatectomy an option but not a requirement. Follow-up treatment involves
simply monitoring PSA levels and velocity to detect any abnormal re-growth.
Stage il Stage III Stage IV
Multiple foci contained within the prostate capsule constitute Stage II cancer, for which
-surgical resection and targeted radiation treatment are prescribed. Should the tumor
infiltrate the local surrounding organs (Stage III), surgery and radiation are not sufficient
to kill all of the cancerous tissue. In this case, chemical androgen blockade will be added
to the treatment to mitigate the growth of hormone-responsive tissue. Once the cancer
has reached Stage IV, spreading to the bladder, rectum, bone, and/or lymph nodes,
systemic administration of anti-androgens and cytotoxicants are the only option for
treatment, and are palliative at best, given that the tumor will inevitably progress to
androgen independence and acquire resistance to cytotoxic agents. The design of 11p is
based on creating an alternative to the chemotherapeutic agents that demonstrate toxicity
to all dividing tissues, in hopes that the androgen-independent metastases that still
express high levels of androgen receptor experience enhanced toxicity compared to
healthy tissue.
t National Cancer Institute, retrieved from www.dana-farber.org April 30, 2009.
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Figure 1-4: The bifunctional drug cisplatin is central to the 93% cure rate of
testicular cancer
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Cisplatin forms DNA adducts and crosslinks, creating a kink in the DNA structure that is
recognized with very high affinity (KD~ 60 pM) by the human upstream binding factor
(hUBF), which normally promotes the transcription of ribosomal RNA. This receptor-
adduct interaction can A) shield the adduct from repair, or B) hijack hUBF away from its
native function. Either mechanism eventually leads to cell death.3
6
,
37
,
87
- Chapter 1: Design of a Programmable Genotoxicant -
Figure 1-5: A library of programmable genotoxicants has been created against
cancers expressing steroid receptors
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The Essigmann Laboratory has developed the technology to design and assemble
programmable genotoxicants against human cancers. A DNA-damaging warhead from
column A can be tethered by a linker featuring variable length and functionality from
column B to a ligand for a target receptor in column C. The work described in this report
concerns the aniline mustard tethered to the 111P position of an androgen receptor ligand
based on RU-486 by a carbamate amine linker, and is referred to as 11s -dichloro, shown
below.
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Figure 1-6: The 11P compounds show affinity for the androgen receptor
comparable to the synthetic androgen R1881
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In LNCaP cell extract, 11p-dichloro (11%) and 11p-dimethoxy (18%) were shown to
effectively compete away the binding of the reference compound 3H-R1881, indicating
affinity- for the androgen receptor on the order of magnitude of the native androgen
testosterone (19%24, not shown). Adapted from Marquis et al. (2005)52.
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Figure 1-7: Toxicity of 11P to prostate cancer cell lines in vitro exceeds that of the
aniline mustard chlorambucil
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I11 elicited markedly more toxicity than chlorambucil against prostate cancer cell lines
in vitro. The AR-dependent LNCaP cell line (squares) showed significantly higher
sensitivity to 1 1p than the AR-independent cell lines DU-145 (diamonds) and PC-3
(circles). Figure courtesy of Shawn Hillier.
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Figure 1-8: 11P inhibits LNCaP xenograft tumors and is well-tolerated by the host
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Subcutaneous LNCaP xenograft tumors were implanted into mice treated with either
vehicle (open circles) or vehicle with 11p (filled circles). The mice receiving 11 P
showed neither tumor growth nor peripheral toxicity from the treatment. Adapted from
Marquis et al. (2005).
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Figure 1-9: Cytochrome P450 catalyzes xenobiotic oxidations through a cycling of
the oxidation states of heme iron
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Substrate R-H diffuses into the active site of P450, displacing water from ferrous heme
iron [A->B]. NADPH supplies an electron to reduce iron to its ferric form [C] before
being oxidized [D]. A proton and an electron from NADPH reduce the active site to
peroxo-iron [E]. Water is generated as the iron temporarily takes a +5 oxidation state [F]
before the R-H bond of the substrate binds the oxygen [G] and restores iron to its initial
state. Water displaces the oxidized product. Crystal structure of CYP3A4 88 shown with
heme group exposed at center. Redox cycle figure adapted from Casarett & Doull's
Toxicology89.
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Figure 1-10: Aflatoxin B1 and cyclophosphamide are activated by P450 with
divergent consequences
a) Aflatoxin B1 (AFB1) is epoxidized by P450 to AFB 1-8,9-oxide, which forms a
mutagenic lesion at N7 of guanine. Figure adapted from Smela et al. 200290.
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b) The pro-drug cyclophosphamide is activated by P450 to 4'-hydroxycyclophosphamide.
This rearranges to aldophosphamide, which decomposes into phosphoramide mustard and
acrolein, both capable of forming covalent adducts with DNA
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C hapter 2: Kinetics and Product Spectrum
of the Hydrolysis of 116-dichloro
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Introduction
Nitrogen, and in particular, aniline mustards are an integral part of the
chemotherapeutic regimens of many human cancers. These agents are frequently used in
combination with other compounds' 2. The high non-specific toxicity of these alkylating
agents, affecting both tumor and healthy cells, makes it very important to monitor and
control the exposure patterns of patients. As with any drug, calibration of the treatment
schedule depends on precise characterization of the stability of the compound both in
vitro and in vivo. The nitrogen mustards undergo an intramolecular ring-closing to form
an electrophilic aziridinium ion known to react covalently with nucleophilic loci of DNA,
with the N7 position of guanine being a primary site of adduction (Figure 2-1)3.
Subsequently, the bifunctional mustard can generate a second electrophile through an
analogous aziridinium formation, yielding a reactive species held in close proximity to
DNA, thus potentiating a second hit on DNA via an intra-molecular reaction. This
second aziridinium ring can generate an intra- or interstrand crosslink with DNA, the
latter leading to potentially lethal double-strand breaks upon the processive failure of
replication machinery4 7 .
The target sites on DNA are not the only nucleophiles that can attack the
electrophilic sites generated by a nitrogen mustard. In any aqueous system, the
aziridinium ion can be hydrolyzed by water, yielding a comparatively innocuous
hydroxyethyl byproduct lacking the leaving group necessary to re-form the aziridinium
electrophile (Figure 2-2). The kinetics of this process, independent of any enzymatic
conversion, represent the baseline rate of inactivation of these compounds. Singly-
hydrolyzed mustards can still form mono-adducts with DNA, but these lesions, as well as
intrastrand crosslinks, are removed through nucleotide excision repair8 . Both chloroethyl
arms must be intact in order to form the more deleterious interstrand crosslink.
A novel bifunctional aniline mustard tethered to a steroid moiety has been
synthesized and shown to kill selectively LNCaP prostate cancer cells in vivo and in
vitro. This compound, l Ip-dichlorot (l1lp), has been shown to generate DNA adducts
and disrupt gene expression normally promoted by the androgen receptor (AR)"'10 ,
2-(6-((8S,11S,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17 dodecahydro-1H-
cyclopenta[a]phenanthren- l-yl)hexylamino)ethyl 3-(4-(bis(2-chloroethyl)amino)phenyl)propylcarbamate
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leading to cell cycle arrest and apoptosis. The working hypothesis governing the
mechanism of toxicity of 11P involves a combination of two distinct pathways, each
dependent on and the high levels of androgen receptor expression in prostate cancer.
DNA adducts formed by 11P may be shielded from nucleotide excision repair by
interaction with the androgen receptor, causing persistent damage. The affinity of 11p
and 11-DNA adducts to the androgen receptor may also hijack the ability of AR to
promote gene transcription necessary for cell division. These two pathways may work in
concert to elicit a more potent toxic response than a co-administration of DNA alkylating
agents and AR inhibitors as separate molecular entities. Like all aniline mustards, 11 is
susceptible to hydrolytic decomposition. In addition, any xenobiotic agent is subject to
metabolic transformation. A combination of hydrolytic and metabolic pathways may
transform 11P into any number of daughter species, each potentially demonstrating DNA
adduction and AR binding capabilities distinct from the parent compound.
Before studying the enzymatic metabolism of 11p, it was necessary to determine
the baseline inactivation level of the compound through hydrolysis, such that the
spectrum of daughter species produced after introduction of l11 into a biological system
could be parsed into those arising through simple hydrolysis and those resulting from
enzymatic conversion. Assuming enzymatic conversion was only relevant in a biological
system, the difference in compositions between the spectra of l11 and daughter
compounds arising from a system including metabolic machinery and one without
defined the contribution of that metabolic machinery to the total conversion of 11p to its
products.
Clinically-used alkylating agents include several drugs whose reactive
electrophiles result from the formation of aziridinium rings, for example, the nitrogen
mustards mechlorethamine, cyclophosphamide, and ifosfamide; and the aniline mustards
chlorambucil and melphalan (Figure 2-3). While cyclophosphamide and ifosfamide are
pro-drugs requiring enzymatic activation, all of these compounds generate electrophiles
through nucleophilic attack by the nitrogen lone pair on the terminal carbon of the
chloroethyl arm. Displacement of the leaving group is slowed by increasing local
concentration of free chloride, which is naturally present at ~100mM in plasma, thus
rendering the rate of formation of the aziridinium and, consequently, the propensity for
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covalent attachment to cellular nucleophiles, strongly compartment-specific",". Ideally,
the aziridinium species would not form until the agent has diffused or been transported to
the vicinity of its target nucleophile-i.e., DNA in the nucleus. It is reasonable to expect
that a given dose of compound would yield a level of DNA damage proportional to the
extent to which intact chloroethyl arms or aziridinium ions reach the nucleus.
In work described in this chapter, the rates of hydrolysis of clinically-used
compounds were compared to 11p and related species to assess the timescale within
which presence in an aqueous system would lead to the deactivation of the mustard arms
of I1P. The aniline mustards chlorambucil and melphalan were expected to behave most
like I11, with alkyl chains para to the mustard substituent of a phenyl ring. The
published half-lives for the decomposition of the dichloro forms of these alkylating
agents are summarized in Table 2-1.
A combination of chromatographic and mass spectrometric techniques was used
to measure qualitatively the identities of the daughter species and quantitatively the
disappearance of 11p -dichloro over time. The stability of I11 was assessed in a variety of
relevant aqueous systems: distilled and deionized water (ddH2O), phosphate-buffered
saline (PBS), tissue culture media, and the in vitro metabolism reaction buffer system
without microsomes. The information gleaned from these experiments provided a
backdrop for and facilitated careful qualitative and quantitative analyses of the enzymatic
metabolism of I11 as described in Chapter 3. These data also help develop a more
chemically-rigorous understanding of the results of in vitro toxicity experiments whose
timescales were significantly longer than the half-life of I1P in tissue culture media.
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Materials & Methods
Qualitative hydrolysis of 11P in water and phosphate-buffered saline: In order to
determine the identities of 1$ hydrolysis products and optimize the conditions for their
detection by mass spectrometry, 1 pL of a 20 mM stock of I11 in DMSO was dissolved in
lmL of either ddH20 (RICCA Chemical, Fort Worth, TX) or Dulbecco's PBS
(Invitrogen, Carlsbad, CA) pre-warmed to 37*C. Samples were vortexed to mix and
placed in a 37*C water bath to initiate the reaction. At times 0, 0.5, 1, 1.5, 2, 4, 6, 12, 24,
and 48 hours after initiation, a 50 pL aliquot was taken and stored at -80*C before
separation by liquid chromatography (LC) and analysis by electrospray ionization-time
of flight mass spectrometry (ESI-TOF).
Optimization of chromatography and spectrometry conditions: Solutions comprising
1 pM each of 11p -dichloro, 11 P-monochloro-monomethoxy, and 11p -dimethoxy (Figure
2-4) were prepared in solvents with various ddH20:acetonitrile ratios. These three-
compound samples were used to measure the resolution with which the chromatography
method developed by Hillier et al.9 would separate lIs from its hydrolysis products.
Samples were injected with a 1200 Series LC system into a Sorbax XDB-C18
(2.lx5Omm, 5ptm pore size) column upstream of a 1200 Series diode array detector in
tandem with a 1200 Series ESI-TOF mass spectrometer (all Agilent Technologies, Santa
Clara, CA) in the Mass Spectrometry lab of the MIT Department of Biological
Engineering. Liquid chromatography was performed at a total flow rate of 0.2 mL/min,
with aqueous mobile phase "A" containing 0.25% acetic acid in distilled, deionized water
prepared in-house and organic mobile phase "B" containing 0.25% acetic acid in
methanol. The method program comprised 2 minutes at 50% B followed by a 20-minute
ramp to 100% B, a 5-minute hold at 100% B, a 5-minute ramp back down to 50% B, and
a 3-minute hold at 50% B to re-equilibrate the column. Mass spectrometry was
performed in positive ion mode with source conditions ranging from 300-325*C heated
capillary, 7-15 L/min drying gas (N2, AirGas, Salem, MA), 15-30 psig nebulizer
pressure, and 3000-4500 V needle voltage. Peaks were identified with the Agilent
Analyst QS software package.
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LC-ESI-TOF detection and m/z identification of 11P hydrolysis products: Aliquots
of samples were diluted to 25% acetonitrile for a 1 p.M sample concentration in order to
provide approximately ten picomoles of total material (parent + daughters) per injection.
Liquid chromatography and diode array settings were as described in the previous
section, with mass spectrometry source conditions optimized to 325*C heated capillary,
12 L/min drying gas, 25 psig nebulizer pressure, and 4000 V needle voltage. In the
samples containing PBS, sample flow was diverted to waste downstream of the diode
array for the first two minutes of each method, preventing salts from entering the mass
spectrometer. Peaks were identified with the Agilent Analyst QS software package, with
the mass-to-charge ratio (m/z) of the monoisotopic peak associated with a given
compound used for ion extraction.
Quantitative hydrolysis of 11P in water: Before attempting to characterize the
decomposition of 11 I in the complex aqueous systems of interest, preliminary
experiments were performed in ddH20 in order to optimize operating conditions for mass
spectrometry. Quantitation was achieved through tracking the disappearance of the
fragment associated with the steroid half of the parent compound with a Series 6410
triple quadrupole (QQQ) mass spectrometer (Agilent) in the Tannenbaum Laboratory of
the MIT Department of Biological Engineering.
A 5 pL aliquot of a 0.2 mM solution of l11 in acetonitrile was diluted into
995 p.L of ddH20 for an initial concentration of 1 p.M. The solution was vortexed and
200 pL were immediately withdrawn and transferred to storage at -20'C. The remaining
reaction volume was placed in a 37*C water bath to start the incubation. At 2, 4, 8, and
24 hours after introduction to the water bath, a 200 pL sample was withdrawn,
transferred to a fresh Eppendorf tube, and stored at -20*C for later processing. Before
analysis, 2 pL of a 0.5 mM solution of 1 Ilp-dimethoxy in acetonitrile were added to the
defrosted 200 p.L sample as an internal standard.
Quantitative hydrolysis of 11P in tissue culture media: A 5 pL aliquot of a 2 mM
solution of I11 in acetonitrile was dissolved into LNCaP media, comprising RPMI 1640
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supplemented with 10% fetal bovine serum (Hyclone, Salt Lake City, UT), 1 mM sodium
pyruvate (Invitrogen), 2.5 g/L glucose, and 10 mM HEPES (Invitrogen) to a final volume
of 1 mL for an initial 11$ concentration of 10 pM. This solution was vortexed and a
200 pL aliquot was immediately transferred to a fresh tube, where it was quickly mixed
with 200 pL ice cold acetonitrile containing 0.1% formic acid and 0.5 pM 11p dimethoxy
as an internal standard, vortexed, and spun for 30 minutes at 18,000 g in a
microcentrifuge kept at 4*C. A 300 pL aliquot of supernatant was added to 700 IL
ddH20 to bring the total organic solvent content down to 15%. The 1 mL was then
loaded onto a C18 SepPak (Waters, Milford, MA) equilibrated with a 2 mL wash of 10%
methanol after initial wetting with 2 mL acetonitrile. The sample was washed with 2 mL
of 10% methanol to remove remaining salts and hydrophilic macromolecules and then
eluted with 2 mL of 100% methanol. Eluates were stored at -20*C until immediately
before analysis.
Quantitative hydrolysis of 11P in microsomal metabolism system: Five microliters of
a 0.5 mM solution of I1p in acetonitrile, 50 pL of NADPH Regeneration System A and
10 pL of NADPH Regeneration System B (BD Biosciences, San Jose, CA) were added to
935 pL of 0.1 M potassium phosphate buffer at pH 7.4, representing the in vitro
metabolism machinery without microsomes. Phosphate buffer and NADPH regeneration
system solutions were pre-warmed to 374C. Final system component concentrations
were 2.5 ptM 11p, 1.25 mM NADP*, 3.3 mM glucose-6-phosphate, 0.4 U/mL glucose-6-
phosphate dehydrogenase, 50 pM sodium citrate, and 3.3 mM magnesiun chloride. The
initial solution was vortexed and a 200 pL aliquot was immediately transferred to a fresh
tube, where it was quickly mixed with 200 pL ice cold acetonitrile containing 0.1%
formic acid and 0.5 pM 11p -dimethoxy as an internal standard, vortexed, and spun for 30
minutes at 18,000 g in a microcentrifuge kept at 4*C. The remaining reaction volume
was placed in a 37*C water bath. At 2, 4, 8, and 24 hours after initiation, the system was
quickly removed from the water bath, vortexed to ensure uniformity, and a 200 piL
aliquot was removed, transferred to a new tube, and quenched and centrifuged in the
same manner as the initial sample. A 300 pL aliquot of the supernatant from each sample
was mixed with 700 pL cold ddH20 to bring the total organic content down to 15%. The
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1 mL was then loaded onto a C18 SepPak previously equilibrated to 10% methanol after
wetting with 100% acetonitrile. The sample was washed with 2 mL of 10% methanol to
remove the remaining salts and hydrophilic reaction components and then eluted with
2 mL of 100% methanol. Eluates were stored at -20*C until immediately before analysis.
QQQ detection of 11P and its hydrolysis products in vitro:
Hydrolysis in ddH20. Analyses of hydrolysis experiments were performed on the
Agilent Series 6410 QQQ operating in positive ion mode with source conditions 325*C
heated capillary, 12 L/min drying gas, 25 psig nebulizer pressure, and 4000 V needle
voltage. Samples were delivered as bolus injections with a carrier mobile phase of 0.25%
acetic acid in methanol at 4 pL/min. Multiple reaction monitoring (MIRM) mode was
used to track abundance of each species after optimization of fragmentor voltage and
collision energy for 11p, its hydrolyzed daughter compounds, and the internal standard
(Table 2-2). Abundance traces were smoothed and integrated in Agilent Qualitative
Analysis, with areas under the curve for each of the test species divided by that of the
internal standard from the same injection to normalize for the variable efficiency of the
workup. Normalized AUCs for parent compound were fit as one-phase exponential
decay processes in Prism 5 (GraphPad Software, La Jolla, CA).
Hydrolysis in tissue culture media and microsomal buffer system. Analyses of
hydrolysis experiments in these systems were performed as above but using a carrier
mobile phase of 80% acetonitrile and 0.1% formic acid flowing at 4 pL/min. Multiple
reaction monitoring mode was again used to track abundance of each species after re-
optimizing fragmentor voltage and collision energy for the new mobile phase conditions.
Abundance traces were smoothed and integrated in Agilent Qualitative Analysis, with
areas under the curve for each of the test species divided by that of the internal standard
from the same injection to normalize for the variable efficiency of the workup.
Normalized AUCs for parent compound were fit as one-phase exponential decay
processes in Prism 5.
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Results
Optimization of chromatography and spectrometry conditions: Chromatography
performance was very sensitive to composition of the sample, with 25% acetonitrile
eventually giving the most reproducible separation. Dimethoxy (m/z 708), monochloro-
monomethoxy (712), and dichloro (716) came off the column at 11.4, 13.6, and 14.5
minutes, respectively (Figure 2-5). Identities were corroborated by the characteristic
chlorine isotope patterns. The 11p family of compounds, rich with heteroatoms and
already protonated at the linker secondary amine, gave robust signals with electrospray
conditions at 325'C, 12 L/min drying gas, 25 psig, and 4000 V capillary voltage.
LC-ESI-TOF identification of hydrolysis products: Stability of I1p was tracked
qualitatively by ESI-TOF as disappearance of the ion with m/z 716. Chromatography
conditions were more than sufficient to separate dichloro from its primary hydrolysis
products 1p N,N-2-chloroethyl,2-hydroxyethyl (monohydroxyl, m/z 698), and l11 N,N-
bis-2-hydroxyethyl (dihydroxyl). Singly-hydrolyzed compound eluted at 11.5 minutes
(inconveniently on top of the dimethoxy internal standard). Doubly-hydrolyzed
compound eluted far earlier at 4.9 minutes (Figure 2-6). The strong effect of the presence
of a chlorine atom on the elution time with these chromatography conditions was useful
for establishing the identities of the compounds in each peak. Elution times and m/z
values for all observed species are summarized in Table 2-3.
Interestingly, in searching for the dihydroxyl compound, ion extraction revealed
both the expected dihydroxyl species and a peak with m/z 680 and an isotope pattern
indicating one chlorine atom (Figure 2-7). This species co-eluted with a peak showing
monoisotopic m/z 340, 0.5 mass unit isotope spacing and significantly more abundance
than the singly protonated compound, and as such was classified as the aziridinium
intermediate with either a +2 charge state (340, aziridinium ion and protonated linker
amine) or +1 (680, aziridinium ion, neutral linker). The aziridinium ion was not expected
to be more than a transient intermediate in the hydrolysis cascade; its separation and
detection by LC-ESI-TOF was surprising.
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A peak with m/z 778 and one chlorine eluted two minutes earlier than parent
(12.7 minutes) in the PBS preparations but not the ddH20 ones, indicating a displacement
of chlorine by phosphate to yield a monochloro-monophosphate product (Figure 2-8).
Surprisingly, the corresponding monohydroxyl-monophosphate species (m/z 760) eluted
earlier than the dihydroxyl, opposite the relationship between the monohydroxyl- and
monochloro-monophosphate species. A doubly-phosphorolyzed compound with putative
m/z 840 was not observed.
Also intriguing were two species with m/z 662 and 644, neither containing a
chlorine atom, eluting at 8.6 and 7.7 minutes, respectively. The compound with m/z 662
suggested the formation of a second aziridinium ion after earlier hydrolysis of the other
chloroethyl arm. The dominant m/z for such a species-with positive charges at both the
linker amine and the aziridinium ion-should have been at 331, but none was detected.
Instead, it is proposed that the monovalent species with mass 662 arises from an
intramolecular attack, with the hydroxyethyl oxygen displacing the remaining chlorine to
generate a morpholinyl moiety. This molecule could then undergo further decomposition
through dehydration and rearrangement to a dihydropyrrole (m/z 644). While the
unsaturated carbon-carbon bond in the latter would conjugate with the nitrogen lone pair
and phenyl a-orbitals of the aniline group, the abundance of this species was not
sufficiently above background signal to observe a change in the absorbance spectrum.
Structures for these additional hydrolysis products are shown in Figure 2-9. Dehydration
in the ionization source was ruled out by the distinct elution times of the two species.
QQQ quantitation of 11P hydrolysis: Stability of 11fP was measured through
disappearance of the parent compound. The formic acid in the mobile phases used with
the media and microsomal system experiments made the doubly-charged compound (m/z
358.9) more abundant than the singly-charged version (716.4) that had dominated in both
the ESI-TOF experiments and the quantitative hydrolysis experiment in ddH20. In all
systems, collision conditions were optimized to break the molecule at the carbamate,
likely yielding a fragment (416.3) that would subsequently dehydrate to the target species
with (398.3), representing the unmodified steroid half of the molecule protonated at the
linker amine (Figure 2-10). Normalization to the dimethoxy internal standard (354.9 ->
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398.3 or 708.4 -> 398.3) controlled for the variance in the separation workup, with the
assumption that dimethoxy and dichloro in a given sample would adsorb to and desorb
from the SepPak columns with equal efficiency.
Quantitative hydrolysis in ddH20 and media gave half-lives for dichloro of 0.40
and 3.03 hours, respectively (Figure 2-11). Decomposition of the compound in the
microsomal metabolism system proceeded with nearly identical kinetics as in ddH20
with a half-life of 0.42 hours.
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Discussion
Separation and mass spectrometry of 11P control species: The incremental
decomposition steps of the mustard arms of I11 expected through hydrolysis represent
only very slight changes to the overall molecular structure. As such, it was necessary to
confirm whether chromatography conditions originally derived by Hillier et al.9 would be
sufficient to separate the hydrolysis products with acceptable resolution. The compounds
11p -monochloro and 11p -dimethoxy had been synthesized previously as controls to
assess the roles DNA adduction and crosslinking play in the toxicity of the dichloro
compound 0 . The subtle changes to the substitutions on the aniline nitrogen of these
analogs were seen as a suitable model for testing separation conditions.
While the performance of the chromatography was encouraging, there were
obvious differences in the propensities for each of the compounds to be detected by the
ESI-TOF: the peaks shown in Figure 2-4 arose from equal concentrations of the three
components in the original mixture, which was prepared from pure stocks. As a result,
the analyses by ESI-TOF were considered qualitative only, valuable for identifying
compounds and optimizing conditions for their analysis, but not useful for quantifying
relative abundances of species in a mixture. Furthermore, since many of the hydrolysis
and metabolism experiments required multiple separations to isolate compounds from
complex media, quantitative mass spectrometric data could only be obtained through
inclusion of 11p -dimethoxy as an internal standard.
Product spectrum: The half-life of I11 due to hydrolysis was expected to be strongly
dependent on solvent conditions, with the decomposition rate of the mustard chloroethyl
arms fastest in water and decreasing in systems containing biological macromolecules
onto which I1P can adsorb. In order to quantify the stability of I11 in all of the
preparations relevant to the scope of this study, it was necessary to measure the rate of
hydrolysis of 11$ in tissue culture media and the phosphate buffer containing NADPH
regeneration machinery used in microsomal metabolism systems. While rates were
expected to differ, the product spectrum was expected to be essentially the same in all
systems, comprising dichloro, monohydroxyl, and dihydroxyl.
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The abundance of the dichloro species fell over time with first-order kinetics,
yielding a transient presence of monohydroxyl that was observed to decompose further
into several products. In qualitative experiments with water and phosphate-buffered
saline, 113 decomposed rapidly, with an apparent half-life of approximately three hours
in each. However, these experiments were performed with quantities of I11 well beyond
those that are soluble in purely aqueous solutions. Instead, it is believed that the vast
majority of the I11 introduced into those systems was in suspension, with some material
diffusing into the bulk solution to replace hydrolyzed compound. The precision of the
ESI-TOF enabled the observation of additional daughter species, including
phosphorolyzed compound, intramolecular decomposition of the monochloro-
monohydroxyl to a morpholinyl group, and dehydration of the morpholinyl to a
dihydropyrrole. Rearrangements of bifunctional nitrogen mustards have been previously
reported as mechanisms for the conversion of the active mustard metabolites of
cyclophosphamide and ifosfamide to oxaza- and diazaphospholidines".
Kinetics of 11P hydrolysis: The presence of fetal bovine serum in tissue culture media
ostensibly allowed adsorption of the hydrophobic 1p onto albumin, protecting it from
the bulk solution and consequently increasing its stability. The ramifications of these
data on the design of new in vitro and in vivo experiments and the interpretation of
existing data are crucial. At the end of a two-hour treatment of l11 in tissue culture
media, only 63% of the compound will have avoided at least one hydrolytic
decomposition. The AUC of such treatments must therefore be scaled to account for the
stability of the compound, especially when comparing treatment protocols that involve
exposures of different lengths. Analogous studies of the rate of hydrolysis of melphalan
in cell culture media have shown the compound to be significantly less resistant to
hydrolysis than 1p, with a reported half-life of 1.1 hours". It is reasonable to conclude
that the hydrophobic steroid moiety of Ip increases its adsorption to albumin in the
media, extending the half-life of the mustard arms to 3.03 hours. In fact, melphalan and
chlorambucil derivatives have been synthesized through conjugation to various functional
groups to improve stability in hopes of increasing toxicity15'16.
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The DNA-damaging ability of 11P is central to the mechanism of toxicity
implicated in its design. The ability of the compound to alkylate DNA and subsequently
form crosslinks is strongly dependent on the kinetics of hydrolysis of the mustard moiety.
The number of opportunities for the aziridinium ion to form and to be hydrolyzed by a
nucleophile other than the N7 of guanine is immense-collateral covalent adduction of
proteins and RNA is extremely likely. Furthermore, detoxification of the aziridinium ion
by glutathione has been shown to be a primary means of deactivation of several
alkylating agents, including chlorambucil and melphalan"' 22 . The hydrophobic steroid
moiety distinguishes 1IP from chlorambucil and melphalan, however, as its bulk
transport characteristics should change the residence times in the series of compartments
11p must pass through before reaching nuclear DNA.
Fundamentally, introduction of I1P into any aqueous medium at physiological
temperature and pH will involve a rate of decomposition of the drug that will change the
system behavior from a single reaction of interest to a time-dependent array of analogous
mechanisms comprising I1P and all of its daughter species. In the case of DNA
adduction, if only crosslinks are considered important for toxicity, the rate of hydrolysis
of the first chloroethyl arm is of primary importance: only the parent compound is active,
and the tracking of its disappearance over time is sufficient to derive the AUC. However,
if monoadducts can cause toxicity, or if the interaction between the drug and target
steroid receptors exerts a biological effect independent of the status of the mustard, then
the dynamics of all 1p species are relevant. Based on the dramatic differences in elution
times of the I1P compounds caused by very slight changes to the molecule, it is
reasonable to expect that the distribution of 1p molecules in a complex biological
system would be strongly dependent on, at the very least, the number of chlorine atoms
still present. If there are compartment-specific mechanisms of dysregulation of cellular
function, the partitioning of I1P and all of its daughter compounds will necessarily
influence its effectiveness as a drug.
QQQ as a quantitative analytical tool: The mass spectrometry conditions derived in
the quantitation of hydrolysis were essential in enabling the design of experiments to
determine the locations of metabolic modifications to 11p (Chapter 3) and the effects of
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plasma protein and chloride ion concentration on uptake and stability (Chapter 4).
However, the individual ionization constants for 11 and its daughter species are
different, so quantitation is limited to tracking the disappearance of parent rather than
generating data from which to rate constants for conversions to specific products could be
derived.
Future directions: The kinetics of deactivation of 11p through hydrolysis will have a
strong effect on the eventual design of a delivery system and choice of administration
route. If alkylation damage is the most important of the many potential cellular processes
I1P could disrupt, protection of the chlorine leaving groups is of primary concern in
maximizing the compound's efficacy. Alternatively, should ligand-receptor interactions
elicit the most desirable responses, the hydrolysis of the mustard arms may increase
bioavailability through reducing hydrophobicity. Most likely, multiple biochemical
mechanisms are in play, and parsing the effects of hydrolysis on each would be necessary
to evaluate the opportunity to tailor both drug redesign and clinical dosage regimens to
maximize selective toxicity.
Quantitation of the hydrolysis of 11p in situ through nuclear magnetic resonance
(NMR) would obviate the need for protocol steps that may confound results"7 . If aqueous
systems can inactivate half of the compound in less than thirty minutes, there is an
inevitable loss of precision when measuring the dose-response relationships between 11p
and its putative macromolecular targets in assays of longer duration. Furthermore,
analysis by NMR could confirm the identities of the proposed morpholinyl and
dihydropyrrole derivatives.
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Figure 2-1: Formation of an adduct at the N7 position of guanine
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The lone pair on the N7 position of either purine can attack the electrophilic aziridinium
formed by the nitrogen mustard's intramolecular ring closing. The resulting species can
form intra- or interstrand crosslinks with a second nucleophilic site.
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Figure 2-2: Mechanism of hydrolysis of 11P
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Figure 2-3: Clinically-used nitrogen and aniline mustards
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Figure 2-4: 11P and its related species
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Figure 2-5: Separation and identification of three 11P compounds by LC-ESI-TOF
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Dimethoxy Ip (m/z 708, no chlorines) was originally synthesized as a control incapable
of forming covalent adducts with DNA but likely to have similar biodistribution and
receptor affinity character to the dichloro compound'o. Dimethoxy was stable to
hydrolysis and easily separated from its dichloro and monochloro analogs, allowing its
use as an internal standard for quantitative experiments done on the triple quadrupole
mass spectrometer.
5.05
6.505.
6.0.6.
4.00.
3.0.8 -
2.8.8.-
2.0.8 -
1.8.5 -
6.0"4
0.0.
....... ...... - ...  .. .. ......... 
- - _- . ..... .
- Chapter 2: Hydrolytic fate of liP -
Figure 2-5: Separation and identification of three 11P compounds by LC-ESI-TOF
b) Monochloro-monomethoxy
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Monochloro-monomethoxy 1I1 had been synthesized previously as a control molecule
incapable of forming DNA crosslinks. Chromatography conditions were sufficient to
separate it (elution time 13.6 minutes) from the dichloro species (14.5). Isotope pattern
suggesting C40 and Cl1 confirmed its identity, enabling rapid classification of hydrolysis
products with the same signature.
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Figure 2-5: Separation and identification of three 11p compounds by LC-ESI-TOF
c) Dichloro
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The two-chlorine signature was essential in confirming the identity of 11p as well as that
of its metabolic products described in Chapter 3.
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Figure 2-6: Separation and identification of primary 11p hydrolysis products
a) Total ion chromatogram (m/z 100-1000)
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The 50-100% methanol gradient provided excellent separation of 11P from its primary
hydrolysis products 1 1p-monohydroxyl (elution at 11.5 minutes) and 1 1p-dihydroxyl
(4.9 minutes).
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Figure 2-6: Separation and identification of primary 11P hydrolysis products
b) Mass spectrum of 11p -monohydroxyl
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Mass spectra of primary hydrolysis products of 11P show isotope patterns consistent with
their composition: b) 11p [-monohydroxyl has an m+2 peak with abundance relative to the
monoisotopic 698 consistent with the presence of one 37Cl atom, while c) 11p -dihydroxyl
(monoisotopic m/z 680) shows a sparse m+2 signal resulting only from the presence of
two 3C atoms.
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c) Mass spectrum of 11p -dihydroxyl
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Figure 2-7: Mass spectrum of an intact aziridinium intermediate
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Though sparse, the aziridinium ion was detected by ESI-TOF during an ion extraction at
m/z 680 to isolate doubly-hydrolyzed 11p. This species, still containing a chlorine atom,
eluted six minutes later than the dihydroxyl compound with the same monoisotopic mass;
the difference in prominence of the signals at 682 (see Figure 2-5c) confirned their
respective identities.
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Figure 2-8: Mass spectra of phosphorolyzed 11P species
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Buffer inorganic phosphate ion executed a nucleophilic attack on the aziridinium ion to
generate a phosphorolyzed species (top, 778). The second chloroethyl arm subsequently
hydrolyzed to yield m/z 760.
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Figure 2-9: Mass spectra of secondary hydrolysis products
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Figure 2-10: Fragmentation of 11P for detection by QQQ
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Figure 2-11: Decomposition of 11P as tracked by QQQ
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11 rapidly decomposed in water and the microsomal buffer system with both half-lives
under 30 minutes (ddH20 t/2 = 0.40 h, R2=0.999, microsomal buffer system tr/2 = 0.42 h,
R2=0.999). In tissue culture media supplemented with 10% FBS, Ip was more stable,
with ti/ = 3.03 h, R2=0.613. Error bars represent mean ± standard deviation, with n=3
for all time points.
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Table 2-1: Hydrolysis rates of clinically-used alkylating agents
Compound Cancers ti/2[hours]
Mechlorethamine Hodgkin's lymphoma, lung <0.121
Ifosfamide mustard Lung, cervix, testicle, Ewing's 0.9*13
sarcoma, neuroblastoma
Cyclophosphamide mustard Lymphoma, myeloma,
acute and chronic leukemias, 0.33*2
neuroblastoma, retinoblastoma,
breast, ovary
Chlorambucil Chronic lymphatic leukemia, 0.26"
lymphoma
Melphalan Multiple myleoma, ovary 0.68-0.74**2,12,26
*The pro-drugs cyclophosphamide and ifosfamide decompose into their respective
27-29
mustards following enzymatic activation
**Reported as kcat [min~'].
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Table 2-2: Fragmentation and collision conditions for detection of 11p species by
triple quadrupole mass spectrometry
11p Species
(dominant charge state)
Dichloro (+1)
Dichloro (+2)
Dimethoxy (+1)
Dimethoxy (+2)
Monochloro-monohydroxyl (+2)
Dihydroxyl (+2)
Transition
Q1->Q3
716.4 -> 398.3
358.9 -> 398.3
716.4 -> 398.3
354.9 -> 398.3
349.9 -> 398.3
340.9 -> 398.3
Fragmentation
Voltage
135
110
135
110
110
110
Collision
Energy
35
13
35
17
13
13
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Table 2-3: Elution times and mass-to-charge ratios for 11P hydrolysis products
Compound Monoisotopic m/z Elution time [min]
11p dichloro (parent) 716 14.5
Monochloro-monophosphate 778 12.7
Monochloro-monohydroxyl 698 11.5
Aziridinium ion 680 11.3
Morpholinyl 662 8.6
Dihydropyrrole 644 7.7
Monohydroxyl-monophosphate 760 5.3
Dihydroxyl 680 4.9
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C hapter 3: Exploration of the Kinetics,
Product Spectrum, and Enzyme-Specificity
of the Metabolic Transformations of 11P
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Introduction
Metabolism of xenobiotics
The path from drug candidate to viable therapeutic agent begins with efficacy: a
compound must elicit a desirable biological response even to be considered for further
development. Once the potency has been characterized, the evolution of a therapy
depends on the pharmacokinetics and pharmacodynamics of a system. In order to assess
safety, derive treatment schedules, and choose delivery routes, researchers must quantify
the dose-response relationship in vivo. Of primary concern are the rates of clearance and
metabolic transformations of a given compound. These reactions, comprising simple
hydrolysis, redox chemistry, and conjugation to cofactors, are critical for understanding
both activation and deactivation pathways associated with a compound.
The cytochromes P450, named for their distinct absorbance pattern at 450 nm
when bound to carbon monoxide, are a diverse family of heme-containing
monooxygenases expressed in the endoplasmic reticula of several tissues, with hepatic
activity implicated in catalyzing transformations of both xenobiotics and endogenous
agents'. Substrate specificity for isoforms of P450 is strongly dependent on the structures
of the enzymes. As a result, compounds with thermodynamically-favorable sites for
modification may escape reaction due to an inability to access the active site. Oxidations,
comprising the majority of the reactions catalyzed by P450, can facilitate clearance by
directly increasing the hydrophilicity of a compound or by providing a scaffold for
conjugation to a solubility-enhancing cofactor. The rate and extent of these reactions
strongly influence the exposure associated with a given dose of a compound.
Preliminary study of the metabolism of any drug candidate begins with analysis of
its pharmacophores: compounds with similar molecular structure or shared moieties.
Containing both an aniline mustard and a steroid ring system, Ip is rich with potential
sites of modification (Figure 3-1). As such, the underlying hypothesis guiding the work
described in this chapter was that I 1P would be a substrate for those P450 isoforms
responsible for metabolism of chlorambucil or testosterone.
2-(6-((8S,11 S,13S,14S,17S)-17-Hydroxy-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17 dodecahydro-1H-
cyclopenta[a]phenanthren-1 1-yl)hexylamino)ethyl 3-(4-(bis(2-chloroethyl)amino)phenyl)propylcarbamate
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Metabolism of chlorambucil
The bifunctional aniline mustard 4-[4-bis(2-chloroethyl)aminophenyl]butyric acid
(chlorambucil) features five heteroatoms and a phenyl ring, suggesting the possibility of
N-dealkylation, epoxidation of the phenyl ring, or oxidation near the carboxyl group.
Chlorambucil has been shown to undergo p-oxidation catalyzed by P450 followed by
dehydration to generate 4-[4-bis(2-chloroethyl)aminophenyl]but-3-enoic acid, which is
further processed into phenylacetic acid mustard (PAAM, Figure 3-2)2. PAAM is
significantly more toxic to normal tissues than the parent drug, ostensibly due to
increased bioavailability associated with improved solubility. However, this higher
toxicity narrows its therapeutic window3. Both parent chlorambucil and PAAM can
undergo N-dechloroethylation, rendering them incapable of forming DNA crosslinks and
presumably non-toxic4 .
Metabolism of testosterone
The primary regulatory signaling cascade in the maintenance of prostate
morphology involves the interaction between dihydrotestosterone (DHT) and the
androgen receptor (AR)5 ' 0 . Circulating testosterone readily diffuses into prostate tissue
where it is converted via reaction with 5a-reductase to DHT, which has a seven-fold
higher affinity for the AR than the parent hormone". Testosterone is also susceptible to
oxidation by P450 from either face and at several loci: hydroxyl groups can be added at
positions 1p, 2a/s, 6a/s, 7a, 11$, 15c1p, and 16Ws, and the 17-hydroxyl group can be
oxidized to yield androstenedione (Figure 3-3)124. The regio- and stereoselectivity of
testosterone hydroxylation by P450 has been extensively studied 2"i" 6
Subtle changes in the structure of testosterone can strikingly affect its affinity for
11the androgen receptor . As such, the development of a drug candidate relying on
mimicking that ligand-receptor interaction depends on adequate characterization of the
degree to which metabolism of the parent compound changes its patterns of interaction
with the target protein. Preliminary studies of relative binding affinity between the AR
and 11p compounds as well as an oligonucleotide containing an 11p adduct have been
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performed17 . The dichloro parent shows a relative binding affinity (RBA) to AR of 11%
when compared to R1881, a synthetic androgen compound often used as a benchmark,
with roughly five times the affinity to the AR as testosterone (19.3%)". Interestingly, the
dimethoxy analog is an even better ligand with an RBA of 18%, suggesting that both
ends of the molecule play a role in receptor binding. While this effect could be an artifact
of differential solubility between the two compounds altering their distribution in the
whole-cell extracts used in the binding assays, the pattern nonetheless demonstrates the
sensitivity of the interaction to small structural modifications.
Multiple sites on 11$ may be substrates for any number of isoforms of P450, and
the resulting modifications may enhance or impede the performance of I11 as a drug
candidate. Deleterious modifications analogous to those to which chlorambucil is
susceptible could arise from dechloroethylation of the mustard to reduce DNA
crosslinking potential, while hydroxylation of the steroid could enhance or sabotage the
receptor interactions on which the premise of selective toxicity is based.
In vitro metabolism by liver microsomes
Nearly all xenobiotic agents reaching the bloodstream will eventually undergo
metabolic processing by the liver. Depending on the delivery route, these compounds
may be rapidly absorbed by the portal system before entering systemic circulation, as in
the case of adsorption through the gut wall following oral administration, or they may
diffuse into the liver after achieving systemic bioavailability through intravenous or
intramuscular injection. The array of drugs and their metabolites resulting from first-pass
metabolism by hepatic enzymes is primarily due to interactions with various isoforms of
P45018. These metabolic reactions strongly influence the clearance rate of the active
compound and consequently, the design of the therapeutic regimen. Measuring the
relationship between the administration of a given dose and the time course of the
resultant plasma concentration depends on isolation of a drug and its metabolites from
blood. Before clinical trials, tissue fractions are invaluable for metabolic analysis to
characterize the product spectrum and offer predictive power as to what the extent and
rate of conversion will be in vivo. Furthermore, the identification and characterization of
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metabolites and other biomarkers is essential to the design of the analytical procedures
necessary to measure the dose-exposure relationship.
Sequential differential centrifugations can be used to separate complete cytosolic
(S9) and endoplasmic reticulum (microsomal) fractions from homogenized whole liver
tissue. The resulting preparations demonstrate concentrated metabolic activity and are
central to the in vitro study of xenobiotic transformations and conjugations. Historically,
microsomes derived from animal livers have been a valuable tool for pre-clinical
assessment of the metabolic potential of a drug candidate. However, the correlation
between the hepatic drug metabolism characteristics of humans and that of animal models
is variable'9 . Initial probes of the metabolism of a drug candidate may be performed with
an animal model, such as rat liver microsomes, with the caveat that the activity profile
may be divergent from that of an analogous experiment performed with human material.
The availability of pooled human liver microsomes from organ donors enables the study
of metabolism caused by enzymatic machinery extracted from the species whose disease
states the drugs are actually designed to treat, rather than a model species from which the
information gleaned may not represent the relevant clinical metabolic profile. The
Essigmann Laboratory has used mice as a host for testing the effectiveness of I1P in
treating LNCaP xenograft tumors. As such, this necessitated study of murine metabolism
in addition to rat and human models. In the work described in this chapter, a combination
of preparations was used, including commercially-obtained pooled human, male rat, and
female rat liver microsomes; as well as male and female mouse liver microsomes
prepared in-house.
In work described in this chapter, quantitative levels of conversion were tracked
by using high-pressure liquid chromatography to separate the metabolites of radiolabeled
1Ip. Following the quantitative experiments, unlabeled 1I1 was incubated in analogous
microsomal preparations for qualitative metabolite analysis by liquid chromatography
and electrospray ionization-time of flight mass spectrometry (LC-ESI-TOF). The
diversity of products observed in both series of experiments provoked follow-up studies
using triple quadrupole mass spectrometry (QQQ) in an attempt to identify the locations
of metabolic modifications.
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Drug-drug interactions
Cancer therapy frequently involves the sequential or concurrent administration of
multiple drugs. It is critical to understand the metabolic pathways associated with the
transformations of each drug in order to avoid dangerous drug-drug interactions (DDI) 20.
Should multiple drugs require the same metabolic machinery for activation or clearance,
or if one drug induces or inhibits the expression of an isoform of P450 responsible for the
metabolism of another compound, the pharmacokinetics of the treatment may deviate
substantially from those observed during clinical trials in which the drug candidate is
administered alone. This pathway interference could lead to a higher or lower exposure
for a given compound, potentially rendering it toxic, if it persists in plasma long enough
for consecutive doses to overlap, or inactive, if its clearance is enhanced or
bioavailability impeded. The incidence of adverse drug reactions leading to patient death
may very well be high enough to rival the fatality rates of cancer , thus necessitating
thorough analysis of metabolic profiles in drug development.
Approximately 75% of all xenobiotic metabolism is catalyzed by the cytochromes
P450, with CYPs 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A(4/5) responsible for over
95% of those reactions . Understanding the behavior of a given drug candidate with
respect to this P450 subset is an essential part of the screening process of drug
development. Demonstration that a given compound does not show inhibitory activity
toward these key isoforms in vitro can obviate the need for costlier in vivo assays.
Conversely, if that compound is shown to possess strong activity toward an isoform
crucial to a given disease state, it can be shelved or redesigned at the molecular level in
24
order to balance efficacy with safety . Comparisons of the results in vitro and in vivo
DDI studies have shown sufficient correlations to confirm the predictive power of the in
vitro work2O.
Several strategies are commonly employed to screen drug candidates for
metabolic activity. Monoclonal antibodies against specific isoforms of P450 have proven
useful in parsing the relative contributions of individual isoforms to the composite
metabolic profile of a substrate with multiple labile sites25. The desire for high-
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throughput compound screening has provoked the development of fluorogenic assays that
eliminate the need for time-intensive separations downstream of the reaction26 . Cocktails
of substrates have been used both to inhibit multiple P450 isoforms in the same
microsomal preparation and track the conversions of multiple probes via liquid
chromatography and mass spectrometry (LC-MS) 3 0 . The industrial pursuit of new
therapeutic agents has made the need for rapid screening of vast compound libraries a
critical cost-management task. As such, standard assays have been developed to
determine whether a compound is likely to fail in the developmental process due to DDI
arising from specific P450 isoform induction or inhibition.
In order to determine whether 11p is a substrate for or inhibitor of five of these
isoforms, in vitro incubations with a series of human, mouse, or rat liver microsomes
were performed, taking advantage of a high-throughput automated mass spectrometry
technology developed at BioTrove (Woburn, MA). The speed and precision of this
technique enabled rapid analysis, yielding inhibition data for CYP isoforms 1A2, 2C8,
2C9, 2D6, and 3A(4/5).
Isoform-product correlation
With some preliminary information as to which P450 substrates were relevant to
the metabolism of 11p, attempts were made to further characterize the catalysis by
investigating the correlation between isoform activity and product spectra. Incubations of
Ip containing high enough concentrations of probes to selectively inactivate subsets of
P450 isoforms were performed to determine whether the products observed in earlier
experiments could be attributed to specific isoforms of P450. The high sensitivity of the
QQQ enabled detection of trace levels of products and obviated the need for
chromatographic separation of the mixture before analysis. Because several metabolite
species had been identified previously through work done on the ESI-TOF, the mass-to-
charge ratios (m/z) of major metabolites were known, allowing the conditions for their
detection by MS-MS to be derived quickly.
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Materials & Methods
Materials: Pooled human liver microsomes (HLM) and male rat liver microsomes
(RLM), each containing 20 mg/mL total protein in 250 mM sucrose, were obtained from
BD Biosciences (Woburn, MA), defrosted and distributed into 50-100 pL aliquots, flash
frozen in liquid nitrogen, and stored at -80*C until use. NADPH regeneration
components, also from BD Biosciences, came in two preparations: Solution A (20X),
comprising 25 mM NADP*, 66 mM glucose-6-phosphate, and 66 mM MgCl 2 in H20;
and Solution B (100X), comprising 40 U/mL glucose-6-phosphate dehydrogenase in
5 mM sodium citrate. Mouse liver microsomes and S9 fractions were prepared in-house.
The NADPH regeneration systems were similarly defrosted and separated into aliquots
before flash freezing and storage at -20*C until use. A 0.1 M potassium phosphate buffer
at pH 7.4 was prepared weekly in 100 mL volumes and stored in a tightly-sealed brown
bottle shielded from light at 4*C. The buffer pH was adjusted each morning that
metabolism incubations were performed and unused volumes were discarded at the
conclusion of each session.
Preparation of mouse liver microsomes and S9 fractions: Five male and six female
four- to six-week-old NIH Swiss Webster mice weighing 25-35 g each were purchased
from Charles River Laboratories (Wilmington, MA). Mice were sacrificed by cervical
dislocation and eviscerated. Livers were perfused through the hepatic portal vein or
abdominal aorta with 1.15% KCl in 0.05 M Tris at pH 7.4 (KCI/Tris) and immediately
resected, washed in ice-cold Dulbecco's phosphate-buffered saline (PBS), and stored on
ice in a Petri dish. Tissue masses were 9-10 g from either gender. Once all livers from a
gender were harvested, they were minced to ~5 mm x 5 mm sections with a razorblade.
Minced liver was then added to four volumes of ice cold KClI/Tris buffer in a 50 mL tube.
The solution was transferred to a 50 mL volume Dounce homogenizer and processed
until uniform (~12 strokes). Ligaments and connective tissue were decanted off.
Homogenate was transferred to two centrifuge tubes and spun at 9,000 g (10,000 rpm) in
a Ti50:1 rotor at under vacuum at 4*C for 30 minutes. Supernatants below the lipid layer
were transferred to new centrifuge tubes, with ten 1 mL aliquots of these S9 fractions
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saved on dry ice. A 50 ptL aliquot of the homogenized S9 fraction from each gender was
saved for later protein content quantification. The remaining supernatants were spun at
100,000 g (28,000 rpm) in an Sw4O swinging bucket rotor under vacuum at 4*C for 60
minutes. The supernatants and lipid layers were removed by Pasteur pipet and discarded.
The red, gelatinous pellets were transferred by spatula to a small, pre-chilled
homogenizer already containing 2 mL KCI/Tris buffer. An additional 500 pL of buffer
was used to wash residual microsomal material from the centrifuge tubes. The solutions
were combined and homogenized with 10-12 strokes. A 50 pL aliquot from each gender
was saved for later protein content quantification. The homogenized microsomes were
transferred in 200-250 pL aliquots to fresh tubes and immediately frozen on dry ice.
Frozen microsomes and S9 fractions were stored at -80'C until needed. Protein
concentrations were determined by the Bradford dye binding assay (Bio-Rad
Laboratories, Hercules, CA).
Metabolism of radiolabeled 11p by liver microsomes: Incubations of 14 C 1 1p with
liver microsomes followed the generalized protocol described below, with substrate and
enzyme concentrations, reaction times, and cofactor inclusion or exclusion varied to test
for NADPH dependence, kinetics of conversion, activity of protein, and species and
gender specificity. Aliquots of liver fractions and Solutions A and B were quickly
defrosted in a 37*C water bath and transferred to ice. Potassium phosphate buffer was
pre-warmed to 37*C in a 25 mL glass Erlenmeyer flask. Microsomes were added to
buffer to desired final protein concentration. Subsequently, Solution B (1OOX) and 1 1p
(200X) were added and mixed by swirling. Reactions were initiated by addition of
Solution A (20X) and again mixed by swirling. A small aliquot (5-20 pL) of the
complete reaction system was withdrawn for scintillation counting. Flasks were covered
with parafilm needle-punctured to allow oxygen exchange and secured in a rotating water
bath maintained at 370C, situated to an immersion depth sufficient to ensure temperature
uniformity in the reaction volume during vigorous mixing. Incubations lacking NADPH
machinery were pre-warmed to 37'C and initiated by addition of 11p .
At time points of interest, samples were withdrawn from the flask and mixed with
an equal volume of ice-cold ethyl acetate in a glass sample vial. This mixture was shaken
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vigorously to quench the reaction, dissociate the microsomes, and separate 11p and its
daughter compounds into the organic phase, and allowed to settle on ice for fifteen
minutes. After a second shake and settle, the vial was spun for five minutes at 1,000 g
and 4*C in a swinging bucket centrifuge to enhance the phase separation. A small aliquot
of the organic phase was taken for scintillation counting, with the rest carefully
withdrawn with a Pasteur pipet to avoid disrupting the interface layer and transferred to a
fresh glass vial. A small amount (-1 g) of sodium sulfate powder was added to absorb
residual water from the organic fraction, which was shaken and left to settle on ice. After
fifteen minutes, the vial was shaken and the organic-salt slurry was filtered through a
Pasteur pipet with a cotton plug into a 10 mL pear-shaped glass flask. This flask was
immersed to the liquid level of its contents in a stationary water bath over mild heat. A
gentle stream of filtered air was blown into the flask to speed evaporation of solvent.
While the first ethyl acetate-sodium sulfate system equilibrated, a second equal volume
of ethyl acetate was added to the remaining aqueous fraction, vigorously remixed, and
centrifuged identically to the first. The organic layer of this extraction step was similarly
dehydrated over sodium sulfate and added to the pear-shaped flask through the cotton
plug. An aliquot of the remaining aqueous phase was taken for scintillation counting of
water-soluble metabolism products. After complete evaporation of the ethyl acetate, the
material was redissolved in 100% methanol and a small aliquot was taken for scintillation
counting to quantify total recovery and ensure sufficient activity for detection. Recovery
rates were consistently >60%. Samples were stored at -80*C until immediately before
analysis. All aliquots for activity quantification were mixed with Hionic-Fluor
scintillation fluid (Perkin-Elmer, Waltham, MA) and counted with a Beckman LS1801
liquid scintillation counter (Beckman-Coulter, Fullerton, CA).
Quantification of 4 C 11P species by HPLC-UV-Radio: Reconstituted samples were
separated by reversed-phase HPLC and analyzed with a Series 330 Photodiode Array
(PDA) detector (Varian) in tandem with a Flow Scintillation Analyzer Model 150TR
(Packard Biosciences, Meriden, CT) radiochemical detector.
Chromatography Method 1 was a modified version of a program originally
developed by Hillier et al.3 , using ddH20 with 10% acetonitrile and 10 mM sodium
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acetate as mobile phase "A" and 100% methanol as mobile phase "B." A Sorbax XDB-
C18 column (4.6x250 mm, 5 pM pore size; Agilent, Santa Clara, CA) was used with a
total mobile phase flow rate of 1 mL/min. This method comprised 2 minutes at 0% B,
followed by a 20-minute ramp to 100% B, a 5-minute hold at 100% B, a 5-minute ramp
back down to 0% B, and a 3-minute hold at 0% B to re-equilibrate the column.
Immediately upstream of the radiochemical detector, Ultima-Flo M scintillation fluid
(Perkin-Elmer) was introduced at a flow rate of 2.5 mL/min.
Previous HPLC separations of 1 1p used a ramp from 50-100% B over the same
twenty-minute interval, with 11p usually eluting at or around 95% B. Given the
uncertainty as to the degree to which metabolites of 11p would be less hydrophobic, and
therefore elute earlier, it was necessary to adjust the initial conditions to 0% B in order to
allow all species to be retained on the stationary phase.
Chromatography Method 2, used for the mouse liver microsomal time course,
bypassed the PDA, going straight from column to radiochemical detector to reduce void
volume, and replaced the mobile phases with those used for LC-MS: 0.25% acetic acid in
ddH20 prepared in-house for solvent A; 0.25% acetic acid in methanol for solvent B. A
Sorbax XDB-C18 column (2. 1x50 mm, 5 pM pore size) was again used with a total
solvent flow rate of 0.4 mL/min. This method began with a 2.5-minute hold at 25% B
followed by a 2.5-minute ramp to 45% B, a 20-minute ramp to 75% B, a 5-minute hold at
75% B, a 5-minute ramp back down to 25% B, and a 5-minute hold at 25% B.
Scintillation fluid was added at a rate of 1 mL/min. This method was designed following
the observation that in experiments with unlabeled compound, separated and analyzed by
LC-ESI-TOF as described below, 70% methanol was sufficient to elute I11 from the
C18 columns-the apparent need to reach 100% B on the tandem UV-radiochemical
detector apparatus was an artifact of the large void volume between the column outlet and
the radio detector.
All radio-chromatograms were smoothed with a 6th-order, 25-point Savitzky-
Golay algorithm and integrated in Prism 5 (GraphPad Software, La Jolla, CA) to
determine areas under the curve for separated peaks. Time course experiments were
modeled in Prism 5 as first-order kinetics.
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Preparation of metabolites for identification by mass spectrometry: Incubations of
unlabeled 11p were performed with human, rat, and mouse liver microsomes for
separation and analysis by LC-ESI-TOF. Reactions were prepared with the same
reagents and procedures as those used for the experiments with labeled compound but
with 1mL final reaction volumes. Instead of ethyl acetate extractions, samples at time
points of interest were quenched by addition of 500 ptL of ice-cold acetonitrile, vortexed,
and placed on ice for thirty minutes. Samples were then spun in a microcentrifuge at
18,000 g and 4*C. Supernatants were withdrawn into 10 mL syringes already containing
6 mL cold ddH20 (RICCA) to reduce total organic content to approximately 7%. This
mixture was passed twice through a C18 SepPak (Waters) previously wetted with 100%
acetonitrile and equilibrated to 10% methanol. Loaded columns were washed with 1 mL
ddH20 to remove any lingering salts, and then slowly eluted with two 2.5 mL volumes of
100% methanol. The eluates were evaporated over mild heat and filtered air, and
reconstituted in 25% acetonitrile to match initial conditions for chromatography method 3
described below. Samples were stored at -80*C when immediate analysis was not
feasible.
Detection and identification of 11p metabolites by LC-MS: Samples were injected
with a 1200 Series LC system into a Sorbax XDB-C18 (2.1x50 mm, 5 pm pore size)
column upstream of a 1200 Series diode array detector in tandem with a 1200 Series ESI-
TOF mass spectrometer (all Agilent Technologies, Santa Clara, CA) in the Mass
Spectrometry Laboratory of the MIT Department of Biological Engineering. Liquid
chromatography was performed at a total flow rate of 0.2 mL/min using Method 2
described above. Mass spectrometry was performed in positive ion mode with source
conditions previously optimized at 325*C heated capillary, 12 L/min drying gas (N2 ,
AirGas, Salem, MA), 25 psig nebulizer pressure, and 4000 V needle voltage. Peaks were
identified with the Agilent Analyst QS software package.
DDI Screen of 11P against five P450 substrates: Incubations for each of four
microsomal preparations (pooled human, male mouse, female mouse, and male rat) were
prepared in a 96-well format, all including 0.5 mg/mL microsomal protein and NADPH
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regeneration machinery in the same concentrations as the larger-scale metabolism
experiments but with 50 pL total reaction volumes. The isoform-probe pairs used are
summarized in Figure 3-4. For each preparation, triplicate analyses of eight 1:10 serial
dilutions of ls (ranging from 100 mM to 10 pM) were performed. Reactions were
initiated with addition of Solution A and incubated at 37*C for thirty minutes. Reactions
were quenched with 50 pL of ice-cold acetonitrile containing 0.1% formic acid and
200 nM bupivacaine as an internal standard, and stored on dry ice until analysis.
Measurement of the levels of probe products was performed with a RapidFire high-
throughput injection system (BioTrove, Woburn, MA) coupled to an Agilent Series 6410
triple quadrupole mass spectrometer. Each 10 pL sample was withdrawn from its well,
desalted on a C4 microcolumn cartridge with water : formic acid (FA) : trifluoroacetic
acid (TFA) (99.9% : 0.09%: 0.01%), and back-eluted with acetonitrile : FA : TFA
(99.9%: 0.09%: 0.01%) into the QQQ source. Multiple reaction monitoring (MRM)
mode with source conditions 350'C heated capillary, 13 L/min drying gas, 60 psig
nebulizer pressure, and 4000 V needle voltage was used to measure species abundance.
Transition conditions for the probe metabolites are summarized in Table 3-1. Cycle time
between injections was 6-8 seconds, allowing the processing of plates in a matter of
minutes. Integration of the MRM peak intensities was performed at BioTrove using the
proprietary RapidFire Integrator Software. These data were modeled as enzyme
inhibition processes in Prism 5 to extract an IC50 from the inflection point of the probe
abundance vs. competitor concentration curve for each isoform.
QQQ identification of modification location by fragmentation analysis: Analysis by
triple quadrupole mass spectrometry was performed on the Agilent Series 6410 QQQ
operating in positive ion mode with source conditions 325*C heated capillary, 12 L/min
drying gas, 25 psig nebulizer pressure, and 4000 V needle voltage. Samples were
delivered as bolus injections with a carrier mobile phase of 0.25% acetic acid in methanol
at 4 pL/min. Based on the spectrum of products seen in previous analyses performed on
the ESI-TOF, a method to distinguish structurally the metabolites with identical mass-to-
charge ratios but distinct elution times was devised (Figure 3-5). A set of transitions
were derived and tested to try to determine on which side of the carbamate fragmentation
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site a metabolic reaction had occurred. MRM mode was used to track abundance of each
species after optimization of fragmentor voltage and collision energy for 11p, its
metabolites, and 11p -dimethoxy as an internal standard (Table 3-2). Abundance traces
were smoothed and integrated in Agilent Qualitative Analysis, with areas under the curve
for each of the test species divided by that of the internal standard from the same
injection to normalize for the variable efficiency of the workup.
Isoform elimination screen: In order to determine whether certain P450 isoforms were
responsible for the generation of specific metabolites or subsets of the metabolites of 11p,
a set of elimination assays were performed containing high (>10 Km) concentrations of
probes in various combinations, each designed to leave only one of the major isoforms
active. Values for Km of the individual probes were taken from Walsky and Obach
(2004)24. Based on the results of the DDI screen, tacrine (CYP1A2) was omitted from
the preparations, replaced with mephenytoin for CYP2C 19. Reaction volumes were each
0.5 mL, containing 0.5 mg/mL pooled HLM and all cofactors as previously described.
Incubations lasted thirty minutes and included 1 ptM 11P with: 1) no microsomes;
2) no inhibitors; 3-7) five mixtures, each containing all but one of the inhibitor set; and
8) all five inhibitors. Reactions were initiated with addition of Solution A and quenched
with an equal volume ice-cold acetonitrile containing 0.1% formic acid and 0.5 pM 11p-
dimethoxy as an internal standard. Separations were performed as described previously,
with material loaded onto C18 SepPaks, washed with ddH20, and eluted with 100%
methanol. The high sensitivity of the QQQ obviated the need for sample concentration,
instead allowing 1 ptL bolus injections of each sample, with a 4 pL/min carrier phase of
0.1% formic acid in methanol. Abundance curves were smoothed, integrated, and
normalized to internal standard. AUCs were compared across the individual preparations
to assess the presence, if any, of isoform-specific patterns.
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Results
P450 catalysis depends on NADPH. Incubations with rat or human liver microsomes
showed minimal conversion of parent compound after thirty minutes, with 11p 93%
intact in both pooled HLM (Figure 3-6) and male RLM preparations (Figure 3-7). Trace
abundance of daughter species eluted only slightly earlier than parent, and as such were
considered likely to be singly-hydroxylated, singly-hydrolyzed, or reduced. Even
without the addition of NADPH and its regeneration machinery, there was likely a
baseline level of cofactors present in the microsomal preparation itself. As such, small
levels of conversion were not surprising. The identities of these species would be
analyzed in later experiments by mass spectrometry.
Reactions containing human liver microsomes including the NADPH regeneration
machinery demonstrated extensive conversion of parent to a vast array of product species
at 1 mg/mL microsomal protein. After the thirty-minute incubation period, only 5% of
parent was intact, and the overwhelming majority of products eluted upstream of 11p-
dichloro, with only trace levels of activity representing species that were more
hydrophobic than the parent. Over a dozen species with distinct elution times were
observed, but their separation under these chromatography conditions was less than ideal;
overlapping peaks complicated quantitation. Rat liver microsomes, on the other hand,
were not as active in either extent or diversity: after thirty minutes, >40% of parent was
intact, with four distinct peaks comprising the majority of the metabolite spectrum.
Kinetics of conversion
Protein activity: The macromolecular content of microsomes provided a sufficient
adsorption surface for 11p, minimizing hydrolysis during half-hour incubations. With the
baseline level of inactivation quantified and the dependence of conversion on NADPH
confirmed, it was then necessary to determine how much catalysis was occurring per unit
protein. The near-complete metabolism of 11p in a 1 mg/mL preparation of human liver
microsomes provoked a repeat experiment with 0.5 mg/mL total protein (Figure 3-8) in
hopes of determining which were the major metabolites.
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The extent to which 1 1p was shown to be a substrate to human liver microsomes
encouraged the in-house production of mouse liver microsomes. In order to conserve
material, the reactions with mouse liver microsomes began at 0.5 mg/mL protein. Serial
dilutions of protein (all with the same cofactor content as the 1 mg/mL incubations)
showed near-complete metabolism of 11p (Figure 3-9) after thirty minutes with as little
as 0.25 mg/mL protein, and 0.0625 mg/mL protein was sufficient to metabolize half of
the parent compound. A comparison of the mouse liver incubations shows a loss of both
product diversity and extent of conversion with declining protein, suggesting that
components of the product spectrum arose from multiple hits: after dissociating from the
active site of one enzyme, products could undergo further modifications, through either a
second P450-catalyzed reaction or a rearrangement facilitated by the original
transformation.
Time course of parent disappearance: Male mouse liver microsomes with 0.25 mg/mL
total protein demonstrated sufficient activity to catalyze nearly complete metabolism of
I1p in thirty minutes. In order to measure the kinetics of conversion, incubations at
0.25 mg/mL were prepared with a 10 mL reaction volume in order to include enough
radioactivity for five time points (5, 8, 15, 22, and 30 minutes) without exceeding the
solubility limits of parent compound. Transformation of parent was extremely rapid,
with 75% conversion achieved within five minutes (Figure 3-10). The disappearance of
11p was modeled as first-order exponential decay with a half-life of 2.1 minutes.
Species-specificity: Significant differences in both extent of conversion and identity of
products were observed across the three species analyzed. All were dependent on
NADPH for conversion, but human and mouse microsomes demonstrated far greater
activity. Apropos the goal of assessing mechanisms for drug candidates against a human
disease and the extensive use of mouse models in the Essigmann Laboratory, further
exploration of the rat metabolism kinetics was deemed beyond the scope of this work.
Gender-specificity: Male and female mouse liver microsomes showed minimal
differences in either extent of conversion or elution times of products (Figure 3-11).
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Incubations with 1 mg/mL total protein and NADPH regeneration machinery
demonstrated near-complete (>98%) conversion of 11p after thirty minutes.
Product spectrum: A diverse array of metabolites was observed through analysis by
ESI-TOF, comprising oxidations, N-dealkylation, and dehydrations (Figure 3-12). At
least four different species showing dichloro isotope patterns and with monoisotopic m/z
732 (+16 from parent) were observed with distinct elution times, suggesting hydroxyl
group additions at separate loci. Twice-hydroxylated 11p was also observed with m/z
748. Dehydration (-18) of these putative hydroxylation products was also detected, with
dichloro species appearing at 714 (dehydrated 732) and 712 (twice-dehydrated 748). The
N-deschloroethyl 11p species with m/z 654 and one chlorine was one of the most
abundant metabolites. This N-deschloroethyl daughter compound could undergo
subsequent hydroxylation to m/z 670. Interestingly, there were as many distinct m/z 670
peaks as there were m/z 732 peaks, indicating that severing of the chloroethyl arm
resulted from a separate P450 encounter than the addition of hydroxyl groups, and that
the variety of loci on which hydroxyl groups could be added was just as broad after
N-dealkylation as before. The spectrum of metabolites was broadest in the incubations
with human liver microsomes (Table 3-3). Both male and female mouse liver
microsomes generated product spectra that were subsets of the slate of metabolites
observed in the human preparations, with females demonstrating slightly less conversion
to the N-deschloroethyl 11p than males.
Drug-drug interaction potential
Results of the DDI screens are shown in Figure 3-13 and detailed in Table 3-4.
CYP2C8. 11p was shown to be a potent inhibitor of the metabolism of amodiaquine to
desethylamodiaquine in microsomes from male rats and both genders of mice, with sub-
micromolar IC50 values in mice and an IC50 of <5 pM in rats. However, 11p was
ineffective at preventing the metabolism of amodiaquine when incubated with human
liver microsomes.
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CYP2C9. Diclofenac was extensively oxidized to 4'-hydroxydiclofenac in all microsomal
preparations except for male mice, where -2 ptM Ip was sufficient to inhibit half of the
conversion.
CYP2D6. The O-demethylation of dextromethorphan to dextrorphan was impeded by the
presence of I1P in all systems, with 50% inhibition occurring at concentrations as under
0.5 pM in male mouse microsomal systems.
CYPJA2. Conversion of tacrine to 1-hydroxytacrine was rapid in all tissue preparations.
No amount of 1p effected any change on the rate of tacrine metabolism, such that the
IC50 curve fits for human and mouse microsomes would not converge.
CYP3A. Hydroxylation at the 6p position of testosterone proceeded readily in all tissues
except for those derived from male rat livers. Pooled human liver microsomes were the
most sensitive to 11P, where the IC50 was calculated as 1.25 pM. Both mouse genders
showed 50% inhibition at micromolar concentrations of I1P as well.
Isoform elimination screen: Very few correlations could be extracted from the
incubations of 1p with various competitor cocktails. In all cases, detection focused on
the steroid side of the carbamate, assuming the formic acid carrier phase would keep the
secondary amine protonated and guarantee detection in Q3. Fragments from the mustard
side of the molecule were not observed. Results are summarized in Table 3-5. In all
preparations, the most abundant products were those with monoisotopic m/z 714, 712, or
654, indicating that oxidations (or hydroxylations followed by dehydrations) and N-
dealkylation were the major mechanisms. Interestingly, the location of the
hydroxylations was more prominent on the mustard side of the carbamate, with
transitions 357->398 and 366->398 dominating the intensity of the spectra of products
with modifications on the steroid side of the carbamate.
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Discussion
Extent of metabolism: 11$ was metabolized extensively and rapidly by human and
mouse liver microsomes yet only modestly by rat liver microsomes. All conversions were
dependent on the presence of NADPH; half-hour incubations in either human or rat
microsomes lacking NADPH left more than 90% of the parent compound intact, in
contrast with the previously shown rapid decomposition of 11p in the metabolism
solution lacking microsomes. The protective effect of a macromolecular compartment
onto which 11p could adsorb to escape hydrolysis was pronounced. Gender had minimal
effect on metabolism, which may not be of immediate importance in view of prostate
cancer, but would be important to characterize should 11P prove promising against
cancers outside the prostate.
Product spectrum of 11P: The complexity of 1 1 as a potentially multifunctional drug
candidate necessarily increases the number of transformation events it may experience
between administration and clearance. With high lipophilicity, nine heteroatoms, an
aromatic ring, and a conjugated carbonyl, few loci on the molecule are not putative
substrate sites for modification by P450. The comparison of I1p to its constituent
pharmacophores chlorambucil and testosterone led to the hypothesis that many reactions
would occur, which was confirmed by the diverse array of derivative species observed in
experiments with both radiolabeled and cold material. Additive and subtractive
transformations were observed in all regions of the molecule. Hydrolytic degradation
and enzymatic catabolism of the mustard arms generates a series of derivates incapable of
DNA crosslinking. Oxidations of at least four distinct loci as well as multiple oxidations
on the same molecule give a group of products easily separable by HPLC and likely
possessing different affinities for the AR. Furthermore, the detection of products that had
undergone both oxidation and mustard decomposition indicates that there is, in effect, a
combinatorial array of products arising from metabolism with P450.
The metabolic reactions catalyzed showed only a few consistent signatures: +16,
from addition of an oxygen; -2, from oxidation of a single bond to a double bond; -18,
dehydration; and -62, N-dechloroethylation. Combinations of these transformations
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generate an array of putative products, several of which were observed (Figure 3-14).
Hydrolysis was not a significant source of decomposition given the timescale and
composition of these experiments. However, it is reasonable to expect that the timescale
of hydrolysis would be relevant during an in vivo treatment. As such, each of the additive
metabolic products would also yield a set of corresponding hydrolyzed analogs, such that
the 716->698->680->662->644 sequence observed in the sequential hydrolysis of the
chloroethyl arms described in Chapter 2 would manifest as 732->714->696->678->660 or
748->730->712->694->676, representing the incremental hydrolytic mustard
decompositions on singly- and doubly-oxidized species, respectively. Even though the
replacement of a chlorine atom with a hydroxyl group has the same net change in mass as
dehydration (-18), the loss of chlorine isotope character associated with the former
transformation allows the distinction between the two by mass spectrometry. In all
species, the most common transformation was to m/z 732, indicating hydroxylation of
I1P but persistence of intact dichloro mustard capable of forming DNA crosslinks
The atomic composition of a daughter species can be derived from the mass-to-
charge ratio and isotope pattern of its spectrum. The change in molecular weight from
parent compound indicates the series of reaction or reactions that gave rise to that
particular molecule. However, the ability to pinpoint the locations of the modifications
depends on more advanced techniques. Preliminary attempts to glean some structural
understanding from the mass spectra were made based on the consistency of the
conditions used in the QQQ to fragment 11 and its derivatives at the carbamate linker,
sending the steroid half of the molecule into Q3 for detection. If a particular metabolite
contained a moiety that changed the m/z of the Q3 fragment, the location of the
modification could at least be assigned to the steroid half of the molecule. If, on the other
hand, an 11p derivative yielded a Q3 of 398.3, identical to parent, then any modifications
must have occurred on the mustard half of the molecule. Samples of MRM spectra
illustrating this behavior are shown in Figure 3-15. Analysis of fragmentation patterns
suggested that more modification was occurring on the mustard half of the molecule than
on the steroid half, which was surprising in light of the original hypothesis that the steroid
ring system would be the main target of oxidation.
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Drug-drug interaction screen: Tracking N-dealkylation in amodiaquine, 0-
demethylation of dextromethorphan, and hydroxylation of testosterone and the phenyl
ring in diclofenac, the DDI screens confirmed that 11p would likely compete for the
binding sites of several important isoforms of P450. 1IP demonstrated such negligible
interaction with CYPlA2 that tacrine was omitted from the isoform elimination screen,
replaced instead by S-mephenytoin, the standard substrate for CYP2C19. Because both
in vivo and in vitro toxicity studies performed with 11p involve drug treatments up to
10 pM in media or plasma, IC50 levels below this level were considered noteworthy. The
abundance of deschloroethyl Ip in the in vitro metabolism assays analyzed by ESI-TOF
and the degree to which I1P inhibited the formation of desethylamodiaquine and
dextrorphan suggest that CYP2C8 and CYP2D6 may be important isoforms in the
deactivation of the DNA crosslinking ability of the compound. Similarly, the marked
inhibition of the formation 6p-hydroxytestosterone indicates that CYP3A4 may catalyze
any or all of the hydroxylation products of 1p that were observed.
Isoform-product specificity: Little correlation was observed between the product
spectra and the elimination of specific isoforms. This result can be interpreted in several
ways: a) 1p is a substrate for other isoforms not inhibited by the cocktail and the level
of background conversion rendered parsing of the contributions of the individual
isoforms impossible; b) Ip is a substrate for all of the isoforms tested and the sets of loci
at which the individual isoforms can catalyze a reaction are overlapping; c) the limited
structural information available was not sufficient to distinguish distinct modification
locations on products with the same m/z signal; or d) inhibition was so extensive that the
signals observed were below the noise threshold for quantitative analysis.
Future directions: The relative insolubility of 1p in aqueous systems and the scarcity
of radiolabeled material presented limitations as to the design of in vitro experiments that
quantify conversion, but are even more profound when contemplating in vivo metabolic
exploration. The rapid conversion of 1p to its daughter species in the presence of
microsomes demonstrates the existence of a vast combinatorial array of products with
different solubilities, AR affinities, and DNA binding capabilities. As such, it is
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reasonable to expect that individual members of the spectrum of 11p species arising in
that system may have distinct levels of cytotoxic activity.
In order to more precisely characterize the location and disposition of the
observed metabolic transformations, it would be necessary to use nuclear magnetic
resonance (NMR) or ion trap mass spectrometry (MS"). For NMR, a larger amount of
material and more elaborate purification schemes would be essential in assuring
interpretable spectra. In contrast to metabolic studies on commercially-available
compounds, the limited supplies of radiolabeled 11p for quantitative in vivo studies and
unlabeled 1P for NMR and/or mass spectrometry force significant constraints on
experimental design. Ion trap mass spectrometry in tandem with more effective
chromatography would help elucidate the locations of hydroxylations, as sequential
fragmentations of species with the same m/z but separate elution times could help solve
the structures of the metabolites.
Finally, the potential for metabolites maintaining bifunctional DNA alkylation
ability to create DNA adducts with m/z signatures distinct from those previously
analyzed must be explored. It is consistent with the hypothesis governing the design of
the compound that modifications to the steroid ring will alter receptor affinity, which may
affect the kinetics of both repair of lesions and formation of crosslinks. Quantitative
adduction studies by accelerator mass spectrometry (AMS) 31 do not distinguish adducts
based on the molecular weight of the alkylating species. Monoadducts and crosslinks
derived from both I1P and its metabolic derivatives may be generating the 14C signals
measured in those experiments. While it would be impractical to attempt to synthesize
hypothetical I11 derivatives in order to generate standards for comparison, the
sophistication of the mass spectrometric techniques available in the Tannenbaum
Laboratory would certainly enable the detection of adducts generated by 110 metabolites.
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Figure 3-1: Putative modification loci on 11P
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Dichloro 11p, comprising an aniline mustard, linker with carbamate and secondary
amine, and steroid ring, is susceptible to numerous modifications by P450. On the
mustard, Ip may be a substrate for a) oxidation alpha to nitrogen leading to
dealkylation; b) oxidation of the nitrogen; c) epoxidation of the phenyl ring. The linker
may experience d) p-oxidation similar to that seen in chlorambucil metabolism; e)
oxidation alpha to heteroatoms; f) oxidation of nitrogens. Steroid metabolism catalyzed
by P450 has been observed at g) the 1, 2, 6, 7, 15, and 16 positions, most of which can be
attacked on either face; and h) oxidation of the 17-hydroxyl group to a ketone. It was
assumed that hydroxylation at the 11 position observed by Choi et al.13 would be
sterically hindered by the attached linker. Oxidations on the steroid system leading to
extensions of the conjugated 3-keto group were expected in hopes of altering the UV
absorption spectrum of the molecule.
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Chlorambucil (top left) undergoes P450-catalyzed 11p -oxidation and dehydration to 4-[4-
bis(2-chloroethyl)aminophenyl]but-3-enoic acid. This intermediate decomposes to
phenylacetic acid mustard (PAAM, bottom right). Both chlorambucil and PAAM are
subject to N-dechloroethylation to their corresponding monofunctional products.
Adapted from Pettersson-Fernholm et al.
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Figure 3-2: Chlorambucil metabolism
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Figure 3-3: Testosterone Metabolism
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Figure 3-4: DDI probes and their tracked metabolites
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Figure 3-5: 11P metabolite fragmentation patterns
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Figure 3-5: 11P metabolite fragmentation patterns
c) Metabolites with multiple
modifications may yield different
Q3 fragments from the same QI
signal. For example, the species
with m/z 748.4 indicates two added
oxygen atoms, but may yield
fragments with zero (398.3), one
(414.3), or two (430.3) oxygens
added to the steroid half of the
molecule, thus also elucidating the
composition of the mustard half.
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Figure 3-6: Conversion of 11p in pooled human liver microsomes (1 mg/mL)
requires NADPH
a) Incubation with microsomes and no NADPH yielded minimal conversion of parent
compound.
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b) With cofactors, the human liver microsomes were potent metabolizers of 11P,
achieving ~95% conversion in thirty minutes and generating over a dozen distinct
daughter species.
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Figure 3-7: Conversion of 11P in male rat liver microsomes (1 mg/mL) depends on
the presence of NADPH
a) Without NADPH, minimal product formation is observed after thirty minutes.
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ehution time [min]
b) Inclusion of NADPH regeneration machinery allows significant metabolite formation,
but the diversity of the product spectrum does not compare to that generated by human
liver microsomes.
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Figure 3-8: Conversion of 11P in pooled human liver microsomes (0.5 mg/mL)
with NADPH regeneration system
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Halving the protein content from the initial reaction conditions reduced both total
conversion of 11 and the diversity of the spectrum of products.
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Figure 3-9: Reaction of 11P with various amounts of male mouse liver microsomes
a) A protein concentration of 0.5 mg/mL is sufficient to catalyze the conversion of >96%
of parent compound
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b) Dilution to 0.25 mg/mL shifts product spectrum but does not appreciably the change
extent to which I11 is metabolized
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Figure 3-9: Reaction of 11P with various amounts of male mouse liver microsomes
c) At 0.125 mg/mL of protein, three-quarters of the starting material have been
metabolized
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d) A thirty-minute incubation with 0.0625 mg/mL of protein is sufficient to convert
nearly half of 11 to products
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Figure 3-10: Kinetics of 11P conversion in male mouse liver microsomes
(0.25 mg/mL with NADPH)
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Figure 3-10: Kinetics of 11P
(0.25 mg/mL with NADPH)
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Figure 3-10: Kinetics of
(0.25 mg/mL with NADPH)
lip conversion in male mouse liver microsomes
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Comparison of 11P conversion in male vs. female mouse liver
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Male (blue) and female (red) mouse liver microsomes prepared in house displayed nearly
identical extents of conversion of 1Ip in thirty minutes at 1 mg/mL total protein, with
<2% parent compound remaining in either reaction. Subtle differences in the elution
times of the major product eluting at ~24 minutes is likely a single hydroxylation at
distinct loci.
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Figure 3-12: Extracted ion chromatograms (XIC) of 11p daughter species
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Figure 3-12: Extracted ion chromatograms (XIC) of 11P daughter species
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Figure 3-12: Extracted ion chromatograms (XIC) of 11p daughter species
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Figure 3-12: Extracted ion chromatograms (XIC) of 11P daughter species
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Figure 3-12: Extracted ion chromatograms (XIC) of 11P daughter species
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Figure 3-12: Extracted ion chromatograms (XIC) of 11P daughter species
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Figure 3-12: Extracted ion chromatograms (XIC) of 11P daughter species
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Figure 3-12: Extracted ion chromatograms (XIC) of 11P daughter species
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Figure 3-12: Extracted ion chromatograms (XIC) of 11p daughter species
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Figure 3-13: Drug-drug interaction screens with pooled human (HLMs), male
mouse (mM[LMs), female mouse (fMLMs), and male rat (mRLMs) liver microsomes
a) DDI screen with Amodiaquine (CYP2C8)
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Figure 3-13: Drug-drug interaction screens with pooled human (HLMs), male
mouse (mMLMs), female mouse (fMLMs), and male rat (mRLMs) liver microsomes
c) DDI screen with Dextromethorphan (CYP2D6)
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Figure 3-13: Drug-drug interaction screens with pooled human (HLMs), male
mouse (mMLMs), female mouse (fMLMs), and male rat (mRLMs) liver microsomes
e) DDI screen with Testosterone (CYP3A)
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Figure 3-14: Combinatorial family of 11p derivatives
Ilp is subject to both additive
and subtractive modifications by
metabolism and hydrolysis.
Modular transformations
associated with oxidation,
dehydration, and decomposition
of the chloroethyl arm yield an
array of potential products.
Underlined m/z values indicate
products observed by ESI-TOF
after a 30 minute incubation of
Ilp with human liver
microsomes (0.5 mg/mL).
Species maintaining two
chlorines and the ability to form
DNA crosslinks are shown in
bold. Normal face type
corresponds to products with
only one chlorine, still capable
of forming DNA monoadducts.
Grey labels indicate products
without DNA-damaging
capability. Solid arrows mark
definite transformation paths.
Faded arrows represent
multiple, indistinguishable paths
to the same m/z product. Red
arrows indicate oxidation to an
alkene or keto group. Black
arrows show oxidation by
addition of one oxygen atom.
Blue arrows represent
dehydration. Green arrows
indicate the loss of a chlorine
through hydrolysis or N-
dealkylation.
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Figure 3-15: MIRM spectra show distinct modification loci on metabolites
a) Product spectra for I11p species maintaining dichloro character were extracted from a
set of MRM transitions for a set of Q 1 mass-to-charge ratios. Panels, from top to bottom:
1) metabolite with m/z 748 showing both modifications on the mustard side of the
carbamate (398), one modification on each side (414), or both modifications on the
steroid side (430); 2) metabolite with m/z 732 showing modifications on either side of the
fragmentation; 3) metabolite with m/z 730 showing four possible configurations,
combining both +0 and -H 2 oxidations; 4) 11p; 5) metabolite with m/z 714 showing a
higher frequency of oxidation occurring on the mustard side of the carbamate (398) than
on the steroid side (396); and 6) metabolite with m/z 712 showing no modifications on
the steroid half of the molecule.
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Figure 3-15: MRM spectra show distinct modification loci on metabolites
b) Top panel: N-deschloroethyl hydroxyl 1 1 is more likely to be oxidized on the steroid
side of the carbamate. Middle panel: N-deschloroethyl 11p with steroid system
unchanged. Bottom panel: metabolite with m/z 714 showing traces of oxidation on
either side of the carbamate (396 or 398) as well as a 414 fragment, indicating a +16 on
the steroid side that must be balanced with a -18 on the mustard side.
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Table 3-1: Reaction and MRM conditions for DDI probes
CYP Substrate [pM] Probe Transition Fragmentation CollisionQ1->Q3 Voltage Energy
2C8 amodiaquine 15 desethylamodiaquine 328->283 100 20
2C9 diclofenac 15 4'-hydroxydiclofenac 312->230 106 33
2D6 dextromethorphan 5 dextrorphan 258->157 156 41
1A2 tacrine 15 1-hydroxytacrine 215->187 100 40
3A4/5 testosterone 50 6p-hydroxytestosterone 305->269 142 13
Conditions for probe detection were previously optimized for the Agilent 6410 Triple
Quadrupole mass spectrometer at BioTrove (Woburn, MA).
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Table 3-2: MRM transition conditions for 110 species
Description
Dihydroxy 11p
Hydroxy 111
748 -H20
1113 dichloro
732 -H20
748 -2H20
708 11p dimethoxy
670 Hydroxydeschloroethyl 11p3
Modification
Zones
+20 M
+0 M, +0 S
748
732
730
716
714
m/z
(+1)
Fragmentation
Voltage
110
110
654 Deschloroethyl 11P (-EtC1 M) 327->398 115 13
Metabolites observed were classified as having modifications on the mustard (M) or
steroid (S) side of the Q2 fragmentation at the carbamate (Figure 3-5). All Q1 signals
arose from the +2 charge state of the analytes, and all Q3 signals represent the steroid
side of the molecule after fragmentation. Separate elution times of {m, m-18} pairs
observed by ESI-TOF ruled out dehydration in the Q2. Derivatives of parent I11 with
the same Q1 but different Q3 indicate distinct modification loci. Combinations of
oxidations (+0 or -H2) and dehydrations (-H20) occurring on one or both sides of the
fragmentation were examined. Products arising from dealkylation of the mustard
nitrogen are annotated as (-EtCl M).
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+0 M
+O S
+0 M, -H2 M
+O S, -H2 S
Parent
-H2 S
-H2 M
-H20 S,+O M
-2H2 S
-H2 M, -H2 S
-2H2 M
Internal Standard
+0 M, (-EtC1 M)
+O S, (-EtC1 M)
Collision
Energy
13
15
712
Transition
Q1->Q3
374->398
374->414
366->398
366->414
365->398
365->412
358->398
357->396
357->398
357->414
356->394
356->396
356->398
354->398
335->398
335->414
110
125
110
125
130
125
135
135
115
110
115
115
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Table 3-3: Relative abundance of the 11p derivatives generated in human and
mouse liver microsomes as detected by LC-ESI-TOF
m/z Pooled human Male mouse Female mouse
748 ++ ++ ++
732 ++++ ++++ ++++
730 ++ + +
714 +++ ++ +++
712 +++ + ++
698 ++ ++ ++
686 +
684 +
680 + + +
678 +
676 +
670 +++ ++ +
662 + + +
654 ++ ++ +
652 +
644 +
These data represent thirty minute incubations with NADPH regeneration machinery and
0.5 mg/mL total protein. Mouse liver microsomes from either gender displayed spectra
representing roughly equivalent subsets of the product species formed in human
preparations, with female mice showing slightly less propensity for N-dealkylation. In
both species, the dominant products were multiple single oxidations to m/z 732 at distinct
loci as evidenced by chromatographic separation.
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Table 3-4: DDI Screen
Probe (Isoform)
Amodiaquine (2C8)
Diclofenac (2C9)
Dextromethorphan (2D6)
Tacrine (1A2)
Testosterone (3A)
IC50 results
Pooled HLM
22.6
(3.42-150.)
R2=0.641
31.8
(5.59-181.)
R2=0.726
2.25
(0.815-6.190)
R2=0.855
N/A
1.25
(0.640-2.42)
R2=0.926
Male MLM
0.644
(0.374-1.11)
R2=0.955
2.06
(0.493-8.56)
R2=0.745
0.454
(0.285-0.723)
R2=0.968
N/A
3.25
(2.42-4.36)
R2=0.986
Female MLM
0.239
(0.0782-0.728)
R2=0.845
10.8
(3.46-33.8)
R2=0.791
1.17
(0.630-2.18)
R2=0.935
N/A
9.62
(6.02-15.4)
R2=0.958
All IC50 values represent 11p [ptM], with ranges in parentheses representing the 95%
confidence interval. Goodness of fit is reported as R2. Each dataset comprised 24 points
from triplicate biological replicates of the eight serial dilutions of inhibitor. Fields
marked N/A indicate a failure of the dataset to converge to a one-site competitive binding
curve. Values under 10 pM are shown in bold, indicating an inhibition potential likely to
be relevant in the in vitro and in vivo assays performed in the Essigmann Laboratory.
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Male RLM
4.45
(2.83-7.01)
R2=0.967
23.3
(5.87-92.5)
R2=0.765
5.86
(3.30-10.4)
R2=0.945
17.5
(6.20-49.1)
R2=0.832
N/A
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Table 3-5: Isoform elimination results
Q >3No No 28 29 D6 3 C AllQ1->Q3 microsomes inhibitors 2C8 2C9 2D6 3A 2C19 inhibitors
374.9->398.3 0.39 0.84 0.35 0.44 0.45 0.30 0.28
374.9->414.3 - - - - 0.016 - - -
366.9->398.3 - 1.9 2.4 2.5 3.5 - 2.8 1.3
366.9->414.3 - 1.1 2.0 2.7 - - 1.4 2.3
365.9->398.3 - 0.55 0.71 - - - 0.59 0.54
358.9->398.3 180 210 320 390 640 320 290 320
357.9->396.3 - - - - - - 0.56 0.74
357.9->398.3 12 16 26 34 37 19 34 42
356.9->398.3 34 46 62 93 130 40 110 110
335.9->398.3 - 0.31 - - - - - -
335.9->414.3 - 1.9 - - - - 1.5 -
327.9->398.3 1.5 37 30 43 51 58 48 38
Product spectra after 30 minutes with 0.5 mg/mL human liver microsomes demonstrated
significantly less conversion of 11p dichloro (bold) to products than observed in
quantitative studies with '4C 11p. The inhibition cocktail consisted of combinations of
20 ptM amodiaquine, 40 pM diclofenac, 50 pM dextromethorphan, 500 pM testosterone,
and 600 pM mephenytoin as described in Materials and Methods.
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Chapter 4: Preliminary Study of the Organismal and
Subcellular Biodistribution of 11P and its Metabolites
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Introduction
The hydrophobicity, multi-functionality, and reactivity of 11p t necessitate a close
examination of the patterns of compound distribution into tissue compartments as a
function of delivery route. Once in plasma, 11p is likely to be extensively protein-bound,
such that the equilibrium between bound and free compound governs the rate of uptake
into cells as well as the hydrolytic stability. At the cellular level, the kinetics of
hydrolysis and extent of metabolic transformations translate the administration of a single
compound into an array of derivatives, each likely to exhibit distinct patterns of
distribution into organelles.
With greasy chloroethyl arms on one end, a lipophilic steroid system on the other,
and a comparatively water-soluble carbamate and protonated (at physiological pH)
secondary amine connecting the two, prediction of the disposition of 11P is beyond
intuition. Possessing characteristics of both androgen receptor antagonists and DNA
alkylating agents, I11 could be exerting its therapeutic or toxic effects in nearly any
organelle of dividing or stationary tissue. While its design and analysis to date have
focused on its ability to damage nuclear DNA, better comprehension of the path the
compound takes between administration and alkylation of DNA would significantly
improve an understanding of the mechanisms relevant to toxicity, as well as guide the
evolution of both clinical dosage regimens and next-generation versions of the molecule.
To date, the studies of the mechanistic effects of 11p have not included
differentiation between the parent dichloro compound and its hydrolytic and metabolic
derivatives. Experiments using radiolabeled material have as a quantitative endpoint
either scintillation counting or accelerator mass spectrometry. Whether those counts arise
from 11p -dichloro, I11 with singly- or doubly-hydrolyzed mustards, hydroxylated or N-
dealkylated 11p, or some combination of modifications is not discernible with the
techniques used. However, the degree to which these transformations influence not only
the biodistribution of the molecules but also their biological activity is likely very
important to both elucidation of the mechanism and design of the therapy in the context
of administration route, formulation, and dosage regimen.
2-(6-((8S,11 S,13S,14S,17S)-17-Hydroxy-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17 dodecahydro-1H-
cyclopenta[a]phenanthren-1 1-yl)hexylamino)ethyl 3-(4-(bis(2-chloroethyl)amino)phenyl)propylcarbamate
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Organismal Distribution
It is valuable at this point to recapitulate the therapeutic strategy governing the
design of these programmable agents. To treat a metastatic cancer whose foci span
diverse tissues (bone, bladder, colon, lymph, etc.), systemic bioavailability is preferred,
as the disease has outgrown the utility of spatially-targeted treatments. Therefore, it is
important to characterize the biodistribution in an animal model with the hopes of
extrapolating to a potential human treatment. The correlation between delivery route and
organ-level distribution will guide optimization of the formulation of the drug candidate.
In conjunction with the experiments demonstrating toxicity against LNCaP
xenografts in a mouse model, biodistribution resulting from the intraperitoneal injections
was measured. The 45 mg/kg doses of a "C-1 1 p preparation with specific activity
1.91 pCi/pmole achieved peak blood levels after fifteen minutes, peak intestinal levels
after two hours, peak liver, lung, and kidney levels after four hours, and peak feces levels
after six hours1 . In work described in this chapter, gavage and intraperitoneal delivery
routes were compared to determine whether systemic bioavailability could be achieved
through oral delivery of 11p suspended in a vegetable oil/DMSO emulsion.
Plasma protein binding
As described in the previous chapters, a diverse array of metabolic and hydrolytic
products of I11 was observed, including derivatives of identical m/z but distinct
modification locations. The degree to which subtle structural changes were sufficient to
alter the elution times of the metabolites from a C18 column suggests that the equilibrium
distribution of I1P and its metabolic products in a complex biological system would be
necessarily multivariate. Species suffering loss of a chlorine atom through hydrolysis or
N-dealkylation demonstrate significantly increased hydrophilicity, and, as such, should
be found in a higher ratio of free to bound drug in plasma. As a model for this system,
the dynamics between free and bound drug were measured as a function of albumin
concentration in an aqueous system. In tandem, to probe further the kinetics of
hydrolysis as a function of chloride ion concentration, the albumin-binding experiments
were performed at either 116 mM or 4 mM chloride, representing the physiological
concentrations of the ion in plasma and cytoplasm, respectively. The sensitivity of triple
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quadrupole mass spectrometry allowed the simultaneous tracking of parent 11p -dichloro,
the singly-hydrolyzed analog 11p -monochloro-monohydroxyl, and doubly-hydrolyzed
compound 11p -dihydroxyl. Based on the differential between the observed half-lives of
11p in aqueous systems with or without protein discussed in Chapter 2, it was expected
that the increasing protein concentration would protect parent compound and slow the
formation of both hydrolysis products. Similarly, the reaction systems with low chloride
were expected to demonstrate the same pattern of hydrolysis in a compressed timescale.
Subcellular distribution
It has been shown that I1P exhibits both agonist and antagonist activity toward
AR, provoking translocation of normally-cytoplasmic AR into the nucleus but impeding
the transcription and translation of genes when applied in competition with native
ligandt. It is unclear whether the physical translocation of an 11p -AR complex increases
delivery of drug to DNA and results in either enhanced or regio-specific adduct
formation. In LNCaP cells, I11 has been shown to form adducts with nuclear DNA'.
Following treatment of a sufficient dose, LNCaP cells undergo apoptotic programmed
death2 . The hypothesis upon which this project was initiated is that DNA adducts formed
by 11p are refractory to nucleotide excision repair if the steroid moiety achieves
sufficient interaction with the bulky androgen receptor, leading to enhanced toxicity in
cancerous cells with levels of androgen receptor expression higher than those in healthy
tissue3 . The work of Proffitt et al. has cast doubt on the validity of this model.
Nevertheless, the drug candidate does cause excessive DNA damage, and inhibiting
replication or repair may provoke an apoptotic response mediated by interactions
between the nucleus and mitochondria. The signaling cascade ensuing from the breach of
the tolerable DNA damage threshold contributes to an apoptotic response2 but is by no
means the only means by which 11p -dichloro could cause cellular dysregulation. As
such, it is unclear whether nuclear DNA damage is either the critical event leading to a
toxicity response or even an appropriate biomarker for correlating exposure level with the
eventual fate of the cell.
i Kyle Proffitt, unpublished data.
136
- Chapter 4: Biodistribution of 11p -
It is noteworthy that the covalent adducts and crosslinks created by 11p in the
DNA of mitochondria, which lack the capacity for nucleotide excision repair4, may be a
more direct and potent trigger of programmed cell death than the analogous species in the
nucleus. The hydrophobicity of I1P suggests that the molecule may diffuse easily across
organelle membranes. Also, the prevalence of a positively-charged linker amine at
physiological pH makes it reasonable to consider the possibility that diffusion across the
mitochondrial outer membrane would be energetically favorable.
In addition to damage to genomic or mitochondrial DNA, the degree to which the
electrophilic aziridinium moiety in activated 11p is attacked by cellular nucleophiles
other than DNA must be considered. Furthermore, direct disruption of membrane
structure caused by 1p saturation of hydrophobic compartments with limited capacity
could trigger apoptosis through ion imbalance and/or depolarization of the mitochondrial
membrane7'8 . In order to ascertain the existence of a pattern of distribution of 11p into
specific cellular fractions, sequential separations were performed on cells treated with
14C- 11 p in vitro, and the activities associated with each compartment at different time
points resulting from various doses were compared. In separate studies, covalent binding
between 11p and protein was explored through incubation with cytochrome c, a small
(molecular weight 12,358) protein for which chromatography and mass spectrometry
conditions were well-characterized in the Tannenbaum Laboratory.
Quantitative structure-activity relationship (QSAR) analysis of 11P species
The array of 1p derivatives ~resulting from hydrolytic and metabolic
transformations will certainly have different interactions with cellular macromolecules
based on their individual capacities for formation of covalent adducts and affinities for
the androgen receptor. Modifications of the steroid system will undoubtedly affect
relative binding affinity'0 , which, in the context of antagonism of the AR-promoted signal
transduction cascades, may abrogate the previously observed partial agonist/partial
antagonist character of the ligand-receptor pair. Metabolic decomposition of the aniline
mustard would eliminate the potential for the formation of a DNA crosslink. As
discussed in Chapter 3, the elucidation of the structures of 11p metabolites was limited to
identifying whether the modification associated with a given mass-to-charge ratio and
137
- Chapter 4: Biodistribution of 11/3 -
fragmentation transition occurred on the mustard or steroid side of the carbamate linkage.
However, in work described in this chapter, it was possible to model the expected
octanol:water partition coefficient (logP) for the putative metabolites to determine the
degree to which the modifications observed would increase or decrease hydrophilicity
and, in turn, potentially influence the sequestration of specific metabolites into
hydrophilic or hydrophobic compartments of cells.
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Materials and Methods
Comparison of 11p bioavailability as a function of delivery route: Female Swiss
Webster mice (Taconic, Germantown, NY) aged 8-10 weeks and fasted overnight were
treated with either a 30 mg/kg intraperitoneal injection of 14C-1 1 p (specific activity
2.4 pCi/pmole) in a Cremophor EL:ethanol emulsion or a 150 mg/kg gavage delivery of
14C-1 1p (specific activity 0.5 gCi/pmole) in a vegetable oil:DMSO emulsion. At 0.5, 1,
2, 4, or 6 hours after administration of compound, mice were sacrificed by asphyxiation
by 90-100% carbon dioxide. The mice were subsequently dissected and the lungs, liver,
kidney, intestines, and feces were collected, with -100 mg samples of each tissue
transferred to pre-weighed 20 mL scintillation vials. Blood (300-500 pL) was collected
via cardiac puncture into a syringe containing EDTA to prevent clotting. Organ fractions
and a 150 pL aliquot of whole blood were homogenized by a 48-hour incubation with
2 mL Solvable (Packard Biosciences, Meriden, CT) at 60*C. Samples were decolorized
by addition of 400 pL hydrogen peroxide over ice and subsequently mixed with 15 mL
Hionic-Fluor scintillation fluid (Packard Biosciences) before quantification of
radioactivity in an LS1801 Liquid Scintillation Counter (Beckman-Coulter, Fullerton,
CA). Whole, unclotted blood was spun for 15 minutes at 1,500 g and 4*C to separate
plasma from hematocytes. A 100 ptL plasma sample was mixed with an equal volume of
ice-cold acetonitrile, vortexed, and spun for two hours at 14,000 g and 4*C. Supernatant
was collected and counted for radioactivity as above. Whole blood, and blood
fractionated into plasma or blood cells were analyzed to quantify how much 14C was
actually in cells, and acetonitrile-extracted plasma supernatant to quantify how much I4C
in plasma was covalently attached, rather than simply adsorbed, to plasma protein.
Contribution of plasma protein and free chloride ion to the stability of 11p: In a 96-
well format, serial dilutions (1, 0.5, 0.25, and 0 mg/mL bovine serum albumin) were
prepared in either ddH20 supplemented with NaCl for a final chloride concentration of
4 mM or Dulbecco's phosphate-buffered saline (PBS, Invitrogen, Carlsbad, CA) for a
final chloride concentration of 116 mM, representing the concentrations of free chloride
in mammalian cytoplasm and plasma, respectively. Albumin concentrations were well
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below human plasma levels of of 3-5 g/dL" but consistent with the ranges used in other
in vitro experiments. Incubations were initiated by addition of a 1 pL aliquot of Ilp in
DMSO to bring the final reaction volume to 50 pL and 1 pM I1p in each well, with each
albumin-chloride concentration pair prepared in triplicate. Plates were stored in an
incubator at 374C. At times 0, 0.5, 1, 2, 3, 4, 6, and 8 hours following initiation, systems
were quenched by addition of 50 pL of ice-cold acetonitrile containing 0.1% formic acid
and 0.5 pM 1 Ip-dimethoxy as internal standard. Plates were transferred to storage at
-20*C until transport over dry ice. Measurement of the levels of 11 r-dichloro, I1Ip-
dimethoxy, 1 Ip-monochloro-monohydroxy, and Ip-dihydroxy species was performed
with a RapidFire high-throughput injection system (BioTrove, Woburn, MA) coupled to
an Agilent Series 6410 triple quadrupole mass spectrometer. Each 10 pL sample was
withdrawn from its well, desalted on a C4 microcolumn cartridge with water : formic
acid (FA) : trifluoroacetic acid (TFA) (99.9% : 0.09% : 0.01%), and back-eluted with
acetonitrile: FA: TFA (99.9%: 0.09%: 0.01%) into the QQQ source. Multiple reaction
monitoring (MRM) mode with source conditions 325'C gas temperature, 12 L/min
drying gas, 25 psig nebulizer pressure, and 4000 V needle voltage was used to measure
species abundance. Integration of the MRM peak intensities was performed at BioTrove
using the proprietary RapidFire Integrator Software. Intensity levels for the compounds
of interest were normalized to that of 11 P-dimethoxy for each well.
Hydrolysis of 11P in cell culture: PC3-AR1 cells obtained courtesy of Shaoyong Chen
(Balk Laboratory, Beth-Israel Deaconess Medical Center, Boston, MA) were grown for
48 hours after an initial seeding of 50,000 cells in each well of a 6-well tissue culture
plate in 2 mL RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum (FBS,
Hyclone, Salt Lake City, UT) and 400 pg/mL G418 (Geneticin, GIBCO). A 200X
solution of I11$ in DMSO was added to fresh media for a final drug concentration of
5 pM. At initiation, media was aspirated from each well and replaced with 2 mL of the
drug-containing preparation. One six-well plate was prepared for each time point. At
times 0, 4, 8, and 24 hours after dosing, media was withdrawn to a fresh tube and mixed
with ice-cold acetonitrile containing 1 piM 11 P-dimethoxy as internal standard. The cells
remaining in each well were disrupted with 2 mL of the same 1 pM 11 p-dimethoxy in ice
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cold acetonitrile, with the resulting solution transferred to a fresh tube. Samples were
mixed by vortexing and centrifuged for 30 minutes at 4*C and 18,000 g. Supernatants
were diluted with ddH20 to 15% organic and passed through a C18 SepPak (Waters)
previously equilibrated to 10% methanol after an initial wetting with 100% acetonitrile.
Samples were eluted with 2 mL 100% methanol and stored at -20*C until immediately
prior to mass spectrometry. Quantitation of parent compound and internal standard was
achieved through bolus injections of the eluates from the media and cellular
compartments into a Series 6410 triple quadrupole mass spectrometer (QQQ, Agilent
Technologies, Santa Clara, CA) operating in positive ion mode with source conditions
325*C gas temperature, 12 L/min drying gas (N2, AirGas, Salem, MA), 25 psig nebulizer
pressure, and 4000 V capillary voltage. Abundance traces were smoothed and integrated
in Agilent Qualitative Analysis, with areas under the curve for parent 11p -dichloro (m/z
716) divided by that of the internal standard 1 1p-dimethoxy (m/z 708) from the same
injection to normalize for the variable efficiency of the workup. Normalized areas under
the curve for parent compound were fit as one-phase exponential decay processes in
Prism 5 (GraphPad Software).
Subcellular distribution of 11P in vitro: LNCaP cells were obtained from the American
Type Culture Collection (Rockville, MD) and grown in 6-well tissue culture plates under
LNCaP media, comprising RPMI 1640 (Invitrogen) supplemented with 10% FBS, 1 mM
sodium pyruvate (Invitrogen), 2.5 g/L glucose, and 10 mM HEPES (Invitrogen). Cells
were seeded at 150,000 per well and allowed to attach and divide for 48 hours under
3 mL media. A 10 mM stock solution of 14C-1 1p was prepared by dissolving 50 pCi of
11p in 200 pL DMSO for a specific activity of 25 ptCi/pmole. At initiation, media was
aspirated from each well of six plates, following which cells were washed with 2 mL PBS
(Invitrogen). After aspiration of the PBS, cells were immediately delivered 1.5 mL of
LNCaP media containing 0, 0.5, 1, 2, 4, or 8 pM 11p with 0.5% DMSO prepared
immediately before administration and pre-warmed to 37*C. Except for the zero time
point, the plates were stored in an incubator at 37*C under humidified 5%
C02/atmospheric air, identical to the conditions under which cells grew after seeding.
Each 6-well plate contained one well with each dose. At times 0, 20 minutes, 40 minutes,
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1 hour, 2 hours, and 4 hours following exposure to compound, one six-well plate was
processed for analysis. Media was withdrawn and collected in an Eppendorf tube labeled
Fraction A. To lift cells off the plate, a 0.5 mL volume of TrypLE (Invitrogen) was
added to each well. The plate was then swirled to ensure complete coverage, and allowed
to incubate at 37*C for three minutes, after which 1 mL of fresh media per well was
added. All subsequent steps were performed in a 4*C cold room unless otherwise noted,
and all separated fractions were stored immediately at 4'C. The resulting 1.5 mL system
of media and detached cells was transferred to an Eppendorf tube and centrifuged for 20
minutes at 1,000 g. Supernatants were collected and labeled Fraction B. The pellet was
resuspended in a hypotonic pH 7.4 aqueous solution with 250 mM sucrose, 10 mM acetic
acid, 10 mM triethanolamine, and 1 mM sodium EDTA in a 15 mL tube and allowed to
rock gently for 20 minutes. Meanwhile, empty tissue culture wells were washed with
500 pL acetonitrile, which was collected and labeled Fraction D. The swelled cells were
then lysed with twelve withdrawals into a 3 mL syringe and expulsions through a 21G
2" needle with the beveled needle tip pressed against the wall of the plastic tube. A
400 pL aliquot of this whole cell lysate was collected and labeled Fraction C. The
remaining 1.1 mL of whole cell lysate was spun at 1,000 g for 15 minutes to pellet nuclei.
The post-nuclear supernatant (PNS) was collected and a 10 IL aliquot was examined
with a hemacytometer to ensure the absence of nuclei. Supernatants with any nuclear
contamination were re-centrifuged and re-examined until separation was complete. The
PNS was subsequently centrifuged at 5,000 g for 20 minutes to pellet mitochondria and
other organelles. This post-mitochondrial supernatant was transferred to a fresh tube
labeled Fraction F. Nuclear and mitochondrial pellets were resuspended in 396 pL TNE
buffer (50 mM Tris, 100 mM NaCl, 10 mM EDTA, pH 7.6), to which 4 ptL of a
0.5 mg/mL solution RNAse A (Qiagen) were added. The resulting solutions were
incubated for 90 minutes at 40'C, following which 50 pL of a 5 mg/mL solution of
Protease K and 50 pL of 5% sodium dodecyl sulfate in TNE were added to bring the
sample volume to 0.5 mL. Samples were subsequently incubated for ninety minutes at
40*C. After cooling to room temperature, 0.5 mL of a phenol:chloroform:isoamyl
alcohol (25:24:1) solution was added to each sample, mixed vigorously, and centrifuged
for ten minutes at 13,000 g and 4*C. From the aqueous layers, 425 pL (avoiding
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disruption of the phase interface) were extracted and mixed with 0.5 mL of a
chloroform:isoamyl alcohol (24:1) solution. These solutions were again shaken
vigorously and centrifuged for ten minutes at 13,000 g and 4*C, following which 350 pL
of the aqueous fraction were transferred to a fresh tube. Next, 35 pL of 3 M sodium
acetate and 800 pL of -20*C 100% ethanol were added to each sample, all of which were
then stored overnight at -20'C. The organic layers from each extraction step were saved
for later scintillation counting, including Fractions E and G, the phenol layers for
mitochondrial and nuclear DNA, respectively, and Fractions H and M, the chloroform
layers for mitochondrial and nuclear DNA, respectively.
After at least twelve hours at -20'C, the samples were centrifuged for 20 minutes at
18,000 g and 4*C. Supernatants were poured off gently, and 1 mL 70% 4*C ethanol was
added to each. Tubes were flicked to re-suspend pellets and samples were centrifuged
again for 30 minutes at 18,000 g and 44C. Supernatants were poured off gently and
pellets were dried with the tip of a Kimwipe before being left open at room temperature
to air dry completely. Finally, samples were redissolved in 100 pL ddH20 and stored at -
20'C for later quantification by accelerator mass spectrometry (AMS), graciously
performed by Rosa Liberman of the Tannenbaum Laboratory.
Purification of DNA was abbreviated from the standard protocol of sequential
proteolysis, extraction, RNA digestion, and second extraction in order to minimize the
number of protocol steps during which binding and distribution patterns could deviate
from those that existed in cells at the time point of interest. Because the genetic material
isolated in these steps was never going to be reintroduced into a living system or used for
any purpose but AMS, the abbreviated separation protocol was deemed sufficient.
Covalent adduction of 11P to cytochrome c: The protocol for assessing covalent
binding between 111P and protein was adapted from Williams et al. 20079. Lyophilized
horse heart cytochrome c was purchased from Sigma Chemical (St. Louis, MO), and
98 mg were reconstituted in 968 pL of 100 mM HEPES at pH 7. Binary serial dilutions
of 11p in DMSO were prepared, spanning protein:compound ratios from 64:1 to 0.125:1.
Reaction volumes of 100 pL containing 8 nmol cytochrome c were incubated at 37*C for
24 hours. Samples were loaded onto a Microcon 3,000 molecular weight cutoff filter
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(Millipore, Bedford, MA) and concentrated with sequential centrifugations of ten minutes
at 9,000 g followed by two 20-minute spins at 13,000 g, sufficient to concentrate material
to ~10 pL. The filter cartridge was inverted over a fresh tube and spun for three minutes
to collect the concentrate, which was subsequently brought up in 100 pL of 50 mM
ammonium bicarbonate at pH 7. Two 25 pL aliquots of the resulting solution were set
aside for digestion by chymotrypsin (1:10, 37*C, 3 hours) or trypsin (1:25, 37'C,
24 hours). Intact protein was extracted with a C18 ZipTip (Millipore) equilibrated to
0.1% trifluoroacetic acid (TFA) in ddH20 after previous wetting with 100% acetonitrile.
Samples were washed with three 10 pL volumes of 0.1% TFA in ddH20 and eluted with
0.1% TFA in 70% acetonitrile. Samples were separated by reversed phase liquid
chromatography on an Agilent Zorbax C18 (2.1 x 50 mm, 5 pM pore size) column with a
50-minute ramp from 5% to 75% B, where aqueous phase A was 0.25% acetic acid in
ddH20 and organic phase B was 0.25% acetic acid in acetonitrile. Chromatography was
performed in tandem with an Agilent Series 1200 electrospray ionization-time of flight
(ESI-TOF) mass spectrometer with m/z range 200-2000 and source conditions 325'C gas
temperature, 10 L/min N2 drying gas, 15 psig nebulizer pressure, and 3000 V ESI
capillary voltage. Chromatograms were analyzed qualitatively with Agilent Analyst QS
software, and protein charge envelopes were deconvolved to obtain the mass of the
singly-charged species.
Molecular modeling of the putative metabolites of 11p: Hypothetical structures with
modifications that may have yielded the transitions observed by QQQ in the experiments
described in Chapters 2 and 3 were derived. These included any logical combination of
N-dechloroethylation (-62), addition of an oxygen atom (+16), oxidation to an alkene or
keto group (-2), and dehydration (-18). Structures were entered into the Molinspiration
Interactive logP (milogP) calculatort (Molinspiration Cheminformatics, Slovensky Grob,
Slovakia) with or without a positive charge on the linker amine. Structures were
categorized by m/z and ranked within groups by the deviation of their calculated milogP
values from the value calculated for unmodified 1 Ip-dichloro.
t Molinspiration Property Calculation Service accessed at www.molinspiration.com.
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Results
Organismal distribution: Gavage delivery was evaluated to test the feasibility of oral
administration in the event that 11p -dichloro goes into clinical use. Gavage delivery of
the vegetable oil emulsion containing 150 mg/kg 11p with specific activity
0.5 pCi/pmole demonstrated significantly higher plasma activity levels than the
corresponding intraperitoneal dose of 30 mg/kg with specific activity 2.44 pCi/pmole.
Concentration of 11P in blood spiked after one hour and fell off with apparent first-order
kinetics over the next several hours. Despite this evident high level of activity in blood, a
commensurate uptake of 11P into organs was not observed (Figure 4-1). Organismal
biodistribution of I1P into tissues was far more extensive following intraperitoneal
delivery despite the absence of a spike in plasma levels upon administration. Separation
of whole blood into plasma and cells revealed that approximately 75% of the
radioactivity at all time points was associated with the cellular compartment (Figure 4-2).
Plasma protein-binding phenomena: Samples corresponding to time points quenched
before a plate was completed and returned to the incubator demonstrated product
precipitation and solvent evaporation that obscured the utility of their data. The samples
taken after two hours, however, were quenched and immediately frozen, and as such,
behaved reliably during downstream analysis. Without reliable data for the zero time
point, kinetics could not be derived. After two hours, nearly all the parent material in the
4 iM chloride samples had hydrolyzed (Figure 4-3), while the dichloro species in the
116 mM wells displayed increasing abundance with increasing concentration of albumin.
Hydrolysis of 11P in cell culture: The half-life of 11p-dichloro in the media
compartment was calculated to be 3.33 hours, with the 95% confidence interval spanning
4.8-8.0 hours. In the cellular compartment, peak abundance of 11p-dichloro occurred
after about six hours and was of the same order of magnitude as the corresponding level
in the media compartment (Figure 4-4).
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Subcellular distribution: Activity levels for each cellular fraction are summarized in
Figure 4-5. Counts for the media Fraction A demonstrated proportionality consistent
with the binary dose serial dilutions and minimal degradation over the six-hour
incubation. However, these activity levels represent total carbon radionuclide without
distinguishing the metabolic and hydrolytic derivatives of 116. Supernatants from the
centrifuged, lysed cells (Fraction B) demonstrated similar proportionality to the initial
dose but represented in most cases less than 5% of the total activity measured, indicating
that very little material was displaced during trypsinization. Activity in Fraction C, the
whole cell lysate, increased over time and measured on average about 10% of the activity
left in the corresponding media fractions. Interestingly, acetonitrile washes of the empty
tissue culture wells (Fraction D) yielded few counts in the doses from 0.5-2 pM, but
yielded levels of activity comparable to the trypsinization supernatant (Fraction B) in the
4 pM and 8 pM doses. Phenol extractions of the post-mitochondrial supernatant
(Fraction E) exhibited a level of activity ranging from about 15-30% of the
corresponding counts in whole cell lysate. The post-mitochondrial supernatant itself
(Fraction F) yielded counts that were roughly twice that observed in Fraction E. Phenol
extraction of the nuclear DNA (Fraction G) yielded 15-20% of the activity found in the
whole cell lysate. Chloroform extraction organic fractions showed no activity above
background. Levels of activity in the nuclear and mitochondrial DNA samples were on
the same order of magnitude.
Covalent binding to non-DNA targets: Attempts to characterize the extent of protein
binding to cytochrome c were unsuccessful, as no protein charge envelopes
corresponding to species with molecular weights of 12,358+653k were observed
(Figure 4-6), where k = the number of molecules of Ip per molecule of protein,
assuming that covalent adduction would involve the loss of one chlorine through
aziridinium formation for -35 and hydrolysis of the other for -18. However, species with
m/z 918 and 1120 were present, indicative of a covalent reaction between I1P and one or
two molecules of HEPES. Based on this result, the incubations were repeated in aqueous
buffer without HEPES, but no protein adduction was detected in this context either.
Despite the absence of modified protein, tryptic and chymotryptic digests were performed
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and analyzed by mass spectrometry as an exercise in developing familiarity with the
equipment and procedures.
Quantitative structure-activity relationship of metabolites: Changes in milogP from
parent compound (7.741 - uncharged linker amine, 5.077 - positively charged linker
amine) caused by single modifications are ranked as follows: hydroxylation of the
carbon beta to the phenyl and linker carbamate, -1.163; hydroxylation of the carbon beta
to the linker amine, -1.150; epoxidation of the phenyl, -1.087; hydroxylation of the
steroid, -0.916; N-dechloroethylation, -0.891; hydroxylation alpha to the mustard
nitrogen, -0.658; oxidation at the 6-7 position of the steroid ring, -0.507; hydroxylation
of the carbon alpha to the linker amine, -0.308; hydroxylation of the phenyl ortho to the
aniline nitrogen, -0.292; oxidation to 17-keto, -0.186; oxidation at the 11-12 position of
the steroid ring, -0.184; oxidation between the phenyl and linker carbamate conjugated to
the phenyl aromatic system, +0.029; and oxidation at the 1-2 position of the steroid ring,
+0.610, with the differential between charge states of the linker amine being 2.664 for
nearly every modification pair. Examples of the combinatorial modifications and their
contributions to changes in solubility approximations are shown in Figure 4-7. A
complete listing of modifications corresponding to all observed m/z values is provided in
Table 4-1.
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Discussion
Organismal distribution
Intraperitoneal administration yielded significant absorption of radiolabeled
compound into organ tissue, consistent with uptake of the compound through portal
circulation. In contrast, gavage delivery of I1P produced a spike in blood concentration
with no commensurate diffusion into parenchyma. The vegetable oil preparation, after
entering the small intestine, most likely mixes with bile to form an emulsion packaged for
circulation as chylomicrons, accounting for the blood concentration and eventual fecal
clearance.
The degree to which the measured radioactivity arises from a spectrum of 1Ip
metabolites rather than unmodified parent compound is not sufficiently understood. It is
possible that the excreted species, if analyzed for structure, would exhibit modifications
from the parent structure that facilitated clearance, while material remaining in systemic
circulation may be more likely to have escaped conversion to a daughter compound. The
assessment of both absolute toxicity and selectivity of toxicity depends critically on
elucidating the distribution fates of both the parent 11p -dichloro and all of its metabolic
derivatives.
Plasma protein-binding phenomena
The degree to which the presence of protein protected I1p from hydrolysis in an
aqueous system was expected to help calibrate the equilibrium kinetics between free and
bound compound. Albumin has been shown to provide at least eleven binding pockets
for small-molecule ligands, and has been crystallized in complex with seven long-chain
saturated fatty acids'. While these are not perfect electronic models for IP, their size
and hydrophobicity are sufficiently comparable to warrant comparison. Unfortunately,
the experiment performed to assess the protection of 1p from hydrolysis by albumin and
the differential rate of hydrolysis as a function of chloride ion concentration was not
adequately optimized to yield kinetic data, though an observation of the most technically
reliable time points demonstrated the expected behavior.
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The relative toxicities of the metabolites of chlorambucil have also been attributed
to plasma protein binding, as the more hydrophilic and toxic phenylacetic acid mustard
metabolite was measured in plasma as 3.2% free drug compared to 0.9% for parent
compound1 3. If the rate of hydrolysis in bulk solution, DNA alkylation potential, and all
other intracellular transport and trafficking processes are equal, it is reasonable to expect
that more DNA adducts and crosslinks would be formed by the metabolite than the parent
compound solely based on its bioavailability. Furthermore, clearance of small-molecule
xenobiotics has been shown to depend on albumin concentration in sandwich-cultured rat
hepatocytes14 . This system is capable of modeling macroscopic plasma and extracellular
transport processes that are absent or irrelevant in in vitro tissue culture studies, where
the surface area to volume ratio of media to cells is significantly higher and the spatial
configuration of cell-cell junctions is artificial.
Between administration and terminal action (either covalent binding to DNA or
clearance), each member of the set of IIP derivatives will likely have a distinct
distribution pathway controlled by plasma protein binding affinity, and the aggregate
exposure to drug experienced by a tumor cell is necessarily the convolution of transport
and activity. For example, it is reasonable to speculate that deschloroethyl- I1p, after
having shed a hydrophobic constituent, may demonstrate increased bioavailability yet
contribute nothing to toxicity. In this case, counting radioactivity to quantify exposure at
the compartment level is insufficient to distinguish carbon labels associated with active
compounds from those associated with inactive metabolites. Mechanistically, it may be
sufficient to consider only the subset of 11p species that still maintain two chlorine
atoms, such that therapeutic effects attributable to the formation of DNA crosslinks can
be parsed from those that arise through other mechanisms, such as protein hijacking or
deactivation through covalent binding to functionally-critical nucleophilic residues1 5 ,
structural disruption of membranes through direct displacement of cholesterol or
inhibition of cholesterol metabolism6 , or oxidative stress and dysregulation of
bioenergetics provoked by redox cycling 6 . The multiplicity of pathways available to
l11 between administration and covalent reaction with target macromolecules is outlined
in Figure 4-8.
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Hydrolysis of 11P in cell culture
The rate of disappearance of 1 Ip-dichloro in media with cells (t12 = 3.33 h) was
superficially only marginally slower than what had been observed in media alone (Figure
2-11; tv2 = 3.03 h). This observation was not statistically significant, but the fact that the
cellular compartment demonstrated concentrations of 11p on the same order of
magnitude as the media compartment was suggestive of the presence of a hydrophobic
sink, most likely the cell membranes. The modeled logD of 11p -dichloro is on the order
of -5.0, suggesting that at equilibrium, a media:cell volume ratio of 100,000:1 would
yield equal amounts of 11 P-dichloro in each compartment. While the media fraction is
not quite water, and the cellular fraction is not quite octanol, the assumption of ~100,000
cells per well and (10 pm) 3 = 1 fL per cell gives a total cellular compartment volume in
the system of 100 pL, which is 5 x 10- the volume of the 2 mL media layer. With these
assumptions, a logD of -6.30 would result in the segregation of equivalent amounts of
material-i.e., more than an order of magnitude away from what was observed.
Regardless of the precision of this calculation, it is reasonable to model the
transport of 11p in this reduced system as shuttling between the following compartments:
1) bound to plasma protein, 2) free in plasma, 3) sequestered in cell membranes, 4) free
in cytoplasm, and 5) covalently bound to cellular targets (Figure 4-8).
Subcellular distribution
Sequential separation and differential centrifugation of cells treated with various
concentrations of 11 p revealed interesting patterns of distribution within cellular
compartments, most strikingly the high level of radioactivity detected in the putative
mitochondrial DNA (mtDNA) fraction. While the methods used were not sufficient to
derive a quantitative measure of DNA damage in terms of adducts per base pair, the
design of such an experiment follows directly from this work. The combination of the
inability of mitochondria to perform nucleotide excision repair4, the hydrophobic-yet-
cationic character of 11p facilitating mitochondrial uptake, and the natural trafficking of
steroid hormones in and around the mitochondria suggests that covalent DNA damage in
that organelle is not only likely to occur but also a probable contributor to the initiation of
an apoptotic cascade.
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Covalent binding to non-DNA targets
The failure to detect covalent adduction between nucleophilic residues of
cytochrome c and I1P is almost certainly attributable to the experimental design, which
preceded the quantitative assessment of the stability of I1P to hydrolysis discussed in
Chapter 2. The 24-hour incubation time used by Williams et al. to study the presence and
extent of protein binding between cytochrome c and reactive aldehydes formed from the
hemolytic decomposition of polyunsaturated fatty acids9 was ideal for the system for
which it was designed but proved to be well beyond the timescale of 11 P hydrolysis in
aqueous systems. Furthermore, the covalent attack of I1P by buffer HEPES contributed
to premature inactivation of the electrophile and raised questions about the use of HEPES
in tissue culture media. It is yet unclear whether 11 P-HEPES adducts form in media at a
rate and to an extent sufficient for substantially detoxifying compound, or at least altering
the effective exposure experienced by cells.
Quantitative structure-activity relationship of metabolites
As discussed in Chapter 3, solving exact structures of metabolites would require
the processing of an amount of material greater than what is currently available, in
addition to labor-intensive syntheses of putative metabolites for direct comparison,
exhaustive purification schemes to facilitate nuclear magnetic resonance, or ion trap mass
spectrometry, all of which were beyond the scope or resources of this work. However,
the ability to narrow down the location of the modifications through triple quad mass
spectrometry allows the modeling of the logP values of the potential compounds and the
development of a preliminary quantitative structure-activity relationship. As expected,
the most dramatic effects on the solubility of the molecule came from removal of chlorine
or dechloroethylation. While it may be an artifact of the limitations of the modeling
algorithm, it is interesting to note that the location of oxidation on the steroid ring had
little influence on theoretical logP, but the addition of a hydroxyl group adjacent to a
linker or mustard heteroatom strongly suggested increased hydrophilicity.
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Future Directions
The therapeutic effects of 11p may extend beyond those of either androgen
ablatives or non-specific toxicants, as the continued high expression of the androgen
receptor in tumor cells having achieved androgen-independence should elicit greater
toxicity in cells arising from prostate tumors than from healthy tissue, even after the
failure of the conventional androgen blockade". Cytotoxicants best achieve toxicity in
dividing cells, including both rapidly-dividing tumor cells and healthy tissue. The
damage to the latter is responsible for side effects that may be as serious to the health of
the patient as the tumors themselves. Healthy tissue with intact nucleotide excision repair
pathways should not sustain damage as persistent or extensive as that found in tumor
tissue. Unlike drug design efforts that seek to target tumor cells specifically, 11p, if
successful, would achieve systemic distribution and penetrate metastatic loci.
The presence or absence of estrogen receptor in ovarian cancer cells has been
shown to have a strong influencet on the kinetics of the formation of adducts between
DNA and E2-7a, a programmable genotoxicant synthesized 8 by the Essigmann
Laboratory comprising an estradiol moiety connected to the aniline mustard warhead by
the carbamate amine linker (Figure 1-5). Estrogen receptor, which demonstrates nuclear
localization even in the absence of ligand' 9, is likely to shield adducts from repair without
influencing the rate of their formation. The androgen receptor, however, is localized to
the cytoplasm in the absence of ligand, and must traverse a more complex path to reach
not only its native function as a transcription factor but also the potentially toxic 11p-
DNA adduct . The degree to which l11 can cause AR traislocation suggests that both
the rate and extent of adduct formation may be enhanced through specific AR-mediated
delivery of Ip from the cytoplasm to DNA.
Fully elucidating the mechanisms of toxicity of 11p observed against cells in
culture and xenografts in the mouse model will require precise characterization of all of
the pathways to covalent binding of cellular macromolecules. Preliminary attempts to
assess the presence and extent of covalent adduction to cytochrome c were unsuccessful
but provoked the posing of a far more fundamental question as to the stability of the
mustard functional groups in aqueous systems. While metabolism studies comprised the
t Sreeja Gopal, unpublished data.
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bulk of the work described in this report, revising the protein adduction efforts would be
worthwhile, especially in the context of the possibility of covalent bonds to either
albumin (or any plasma carrier protein) or the androgen receptor itself. One hypothesis
worth exploring is that if covalent adduction to the androgen receptor occurs (via either
the mustard electrophile or through a Michael addition to the conjugated 3-keto position
of the steroid), residues that are in and around the active site would disproportionately
participate in binding compared to those on the periphery of the molecule. Sequential
incubations and fragmentations to optimize the protocol would be necessary upstream of
mass spectrometry to analyze and deconvolve the data, but if successful, the cartography
of adduction could be solved.
Finally, the lipophilic and cationic character of Ilp makes it a prime candidate for
passive diffusion into the mitochondria, where it would encounter DNA unprotected by
histones and irreparable by the nucleotide excision repair (NER) machinery present in the
nucleus. Mitochondrial DNA demonstrates great redundancy, with the 16 kilobase
genome expressed in bundles localized to the inner membrane in copy numbers of 4-10
per mitochondrion, with 100-1000 mitochondria observed per cell24 . The dynamics of
mitochondrial DNA repair with respect to both machinery and temporal relation to
replication are not sufficiently characterized to derive a hypothesis governing potential
dysregulation by a bulky alkylating agent. Similarly, the regulation of mitochondrial
fission, fusion, and replication does not seem to correlate with the cell cycle, except
during segregation into daughter cells during mitosis 25 -28. Recombination may salvage
mtDNA containing alkylation damage, but it is just as likely that damaged mtDNA copies
would be degraded, with the overall expression level balanced by accelerated replication
of undamaged copies. The high level of oxidation damage incurred by mtDNA due to
respiration necessitates the constitutive expression of base excision repair proteins, so
mechanisms for maintenance of mitochondrial genomic integrity do exist.
The degree to which cancer cells demonstrate different bioenergetics from healthy
tissue, especially as a function of vascularization and nutrient availability, is reflected in
the observation that cancer cells may generate all of the ATP they need through
glycolysis. However, it is also understood that not all cells in a tumor are actively
dividing, with those cells closest to blood vessels more likely to divide and progress to a
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state of being able to infiltrate. In these more rapidly-dividing cells, it is unclear whether
disruption of mitochondrial function caused by alkylation damage would be simply an
energetic block29 or an informational trigger of a cascade of programmed cell death.
However, the absence of NER suggests that an administration pattern resulting in the
accumulation of a lethal level of mtDNA damage while nuclear DNA (nDNA) adduct
levels remain below a toxic threshold could be derived (Figure 4-9). Sequential small
doses of 11p may create both mtDNA and nDNA adducts with measurable dose-
response kinetics. Nuclear DNA would experience a peak adduction level and then
demonstrates repair of adducts over time. Mitochondrial DNA, however, could
experience persistent adduction with each dose resulting in a plateau at that level of
damage. A subsequent dose would begin from that pre-existing level of damage, while
nDNA would have been fully repaired in the time interval. As such, a threshold of
mtDNA damage could be achieved before the triggering of the apoptotic cascade
provoked by excessive nDNA damage or saturation of repair machinery. Increased
persistence of mtDNA damage as compared to nDNA damage has been observed in the
context of reactive oxygen species caused by mitochondrial oxidative phosphorylation 3o.
Furthermore, increasing evidence of the activity of steroid receptors in and around
the mitochondria, including the mitochondrial localization of estrogen receptor beta
(ERp) 3 1-38, suggests that the repair shielding and transcription factor hijacking
mechanisms central to the hypothesis governing the design of these programmable
genotoxicants may apply to mtDNA damage and repair as well as the nDNA originally
targeted. If metabolic transformation of 11p includes aromatization of the A-ring, the
resulting 3-hydroxy functionality could yield affinity for the estrogen receptor-11p
already possesses two unsaturated carbon-carbon bonds conjugated to the 3-keto moiety,
and, as such, could rearrange to an aromatic group without further oxidation.
Competitive binding between modified steroids and estradiol has been shown to occur
with lower IC50 values with ERp than ERa 39, suggesting that the mitochondrial version of
the receptor may be more permissive and therefore more likely to interact with 11p.
Given the electronic favorability of 11p entering the mitochondria, the potential
for interaction between 11p (or its potential DNA adducts) and ERs, and the likelihood
that mitochondrial DNA damage caused by 110 would persist in the absence of
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nucleotide excision repair, it is reasonable to consider the possibility that the apoptotic
cascade observed in vitro could be provoked directly from mitochondrial dysregulation in
addition to, or instead of, a series of nuclear events7,8 ,25 ,29. The high number of individual
mitochondria in a cell and the high copy number of mtDNA molecules in an individual
mitochondrion offer redundancy that protects the cell from a loss of mitochondrial
function following irreparable alkylation damage. However, a probabilistic threshold
could exist if there is either a minimum number of copies or a minimum fraction of the
total copy number that must remain intact to preserve mitochondrial function, and
treatment with 11p is sufficient to breach that threshold. As such, the extents and
timescales of mitochondrial DNA damage and repair, as well as the ensuing dynamic
changes in mitochondrial structure and function must be studied to assess the importance
of the activity of 11p in this critical organelle.
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Figure 4-1: 11P achieves more uniform biodistribution after intraperitoneal
injection than gavage delivery
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Figure 4-2: 11P is absorbed by blood cells following distribution into plasma
mouse gevage: distribution of 11Ip In blood
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Approximately 75% of the radioactivity associated with 11p in blood was in the cellular
pellet following centrifugation of sample collected with EDTA to avoid clotting.
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Figure 4-3: Albumin and high chloride slowed 11P hydrolysis
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After two hours, the presence of 1 mg/mL bovine serum albumin protected 11p -dichloro
from hydrolysis, showing four times the level of intact compound than the reaction with
no protein. The reactions with plasma levels of chloride ion (116 mM) showed
substantially more intact dichloro compound than those prepared with cytoplasmic levels
(4 mM). The adsorption of I11 to plasma protein following administration has a
significant influence on the bioavailability of the drug. All samples were performed in
triplicate; error bars represent 95% confidence intervals.
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Figure 4-4: Comparable levels of 11P were present in the media and cellular
fractions of an in vitro incubation with PC3-AR1 cells
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The rate of disappearance of 11 in the media compartment was comparable to that
observed in hydrolysis in cell culture media. A significant amount of compound was
taken up by cells, with equal partitioning between the two compartments achieved after
six hours.
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Figure 4-5: Sequential separation of system compartments following in vitro
treatment of LNCaP cells with various doses of "C-1lp
a) Media aspirated from wells contained activity proportional to the initial dose at time
points up to six hours after initiation of treatment, indicating no depletion caused by
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Figure 4-5: Sequential separation of system compartments following in vitro
treatment of LNCaP cells with various doses of 14C-11p
c) Whole cell lysate revealed levels of uptake of compound roughly proportional to dose
and nearly-linear kinetics. After six hours, no more than 10% of the total radioactivity
introduced into the system had diffused into cells.
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d) Washes of the plates post-trypsinization indicated measurable quantities of compound
adsorbed to the plastic. However, it is curious that low doses (< 2 pM) leave negligible
residue, while treatments in the dose ranges where toxicity is expected seemed to
generate more debris, cellular or otherwise.
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Figure 4-5: Sequential separation of system compartments following in vitro
treatment of LNCaP cells with various doses of 4C-11p
e) The organic fraction from the first extraction step of the post-nuclear supernatant
showed some lingering activity that was most likely free compound; whether that
represents lIp or some hydrolytic or metabolic derivative is unclear.
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f) Similarly, activity left in the system after the pelleting of nuclei and heavy organelles
seemed to increase with time and be proportional to initial dose.
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Figure 4-5: Sequential separation of system compartments following in vitro
treatment of LNCaP cells with various doses of 14C-11p
g) The levels of activity left in the nuclear fraction following the first extraction step were
comparable to that seen in the mitochondrial DNA phenol phase.
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Figure 4-5: Sequential separation of system compartments following in vitro
treatment of LNCaP cells with various doses of "C-11p
h) Activity associated with nuclear DNA was roughly proportional to dose except in the
case of the 8pM treatment, which seemed to immediately permeate the system and form
DNA adducts but then experienced a lag until later in the treatment.
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i) Interestingly, activity levels in the mitochondrial DNA fraction were on the same order
of magnitude as those in nuclear DNA, which, since mitochondrial DNA comprises
roughly 2% of all cellular DNA, and assuming that the yields of the respective
extractions were comparable, suggests that significantly higher levels of DNA damage on
a per-base-pair basis are occurred in mitochondria.
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Figure 4-6: LC-ESI-TOF of cytochrome c/11p system
a) Cytochrome c charge envelope
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Incubation of 11p with cytochrome c yielded no apparent protein adducts. A single
adduct would have appeared as a charge envelope that deconvolved to MW 13,001. The
most abundant charge state observed at these conditions was the [M+17]"1 7 peak at m/z
728, and absence of a signal at 766 confirmed the lack of these reaction conditions to
allow covalent adducts to form.
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Figure 4-6: LC-ESI-TOF of cytochrome c/11P system
b) HEPES reacts with 11p
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A species with m/z 918 and isotope character suggesting one chlorine atom was
observed, consistent with the product of a reaction between 1p and HEPES. The
displacement of chlorine (-35) and the subsequent attack by HEPES (+237) resulted in a
net +202 change from parent 11p.
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Figure 4-6: LC-ESI-TOF of cytochrome c/11p system
c) HEPES reacts with 1p
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Figure 4-7: QSAR modification analysis
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Deviations from parent 11p -dichloro (top of page) are described in a modular fashion.
Red arrows and small letters indicate locations where addition of an oxygen atom (+16)
was modeled. Green dashed arrows and numbers designate locations of oxidation to an
alkene or keto group (-2). The blue solid arrow indicates an N-dealkylation. The two
example product structures shown correspond a species with m/z 670 (top) with one
mustard arm lost and hydroxylation at position f, p to the linker amine; and a species with
m/z 730 (bottom) with oxidation at the 6-7 position of the steroid and epoxidation at
position c, the aniline phenyl ring (bottom).
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Figure 4-8: Plasma protein binding and subcellular distribution of 11P
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The pathways available to 11p between absorption into the blood stream and formation of
nuclear DNA adducts and crosslinks includes, but is not limited to, equilibrium between
free compound and plasma protein (albumin, shown), sequestration in lipophilic cell
membranes, metabolism in endoplasmic reticulum, and diffusion into mitochondria. In
either the nucleus or the mitochondria, DNA adducts may form. The relative rates of
hydrolysis of parent compound are strongly dependent on chloride ion concentration, but
metabolic transformations may also influence the dynamics of the compound.
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Figure 4-9: Theoretical accumulation of damage in an NER-deficient compartment
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Repeated small doses of an alkylating agent should generate transient damage and repair
patterns in the nuclear compartment. However, irreparable mitochondrial DNA damage
may accumulate over the same time scale, reaching a threshold of toxicity and activating
a program of cell death directly.
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Table 4-1: Predicted milogP values for observed metabolites
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Metabolic modifications to 11p resulted in modular changes to the milogP, with
hydroxylation at the beta position between the carbamate nitrogen and the phenyl ring
generating the highest increase in hydrophilicity without hydrolyzing a mustard
chloroethyl arm. The balance between increasing bioavailability by lowering milogP and
losing AR affinity through steroid ring modification would be one aspect of the next
iteration of compound design.
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